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ENGLISH SUMMARY 
Stress-induced hyperglycaemia commonly occurs during critical illness and has 
been associated with increased morbidity and mortality. The results in the literature 
concerning glycaemic control and nutritional support are, to some extent, 
conflicting and do not provide consensus about optimal protocols for treatment. 
Concerning the control of blood glucose (BG), this thesis hypothesizes that 
mortality can be reduced by reducing BG and/or by reducing the frequency of 
hypoglycaemic events. It also hypothesizes that in clinical practice reduction of BG 
and hypoglycaemic events is best achieved by using model-based decision support 
systems. Concerning nutrition the thesis hypothesizes that nutrition should target 
the patient’s energy expenditure (EE), except for the first few days following the 
insult to the patient, where the caloric target should be below the patients EE. The 
thesis also hypothesizes that in clinical practise accurate estimation of EE cannot be 
done by predictive equations that use anthropometric data, but can be done by a 
novel method, CO2-based calorimetry.  
Evidence from the literature, including the four papers that are the basis of this 
thesis, will be used to examine each of the six hypotheses. 
 
Most of the controlled studies using intensive insulin therapy (IIT) to reduce BG 
have succeeded in lowering BG, but almost all of them resulted in increasing the 
number of patients with hypoglycaemic events. The studies have shown different 
results in terms of mortality, with about half of the studies having resulted in 
reduced mortality and the other half resulting in increased mortality. Lowered 
mortality was not associated with the reduction in BG (p=0.40), nor with the 
reduction in the percentage of patients with severe (BG < 2.2 mmol/l) 
hypoglycaemia (p=0.83). 
A two-dimensional regression analysis with changes in BG and hypoglycaemia as 
independent variables indicated that reduced mortality was associated with reduced 
BG (p=0.05) and reduced frequency of hypoglycaemic events (p=0.07). That 
supports the notion that hyperglycaemia should be reduced to normal BG 
concentrations while avoiding hypoglycaemic events. Clinical studies support the 
hypothesis that a safe reduction in BG is best achieved with the use of a model 
based decision support system. While there are many different systems to do so, 
both rule-based and model-based, the Glucosafe system (using the Glucosafe 
model) has, compared to other systems, shown either bigger or similar reduction in 
BG with no hypoglycaemic events. 
Glucosafe has two major components: the advice module and the model. The 
quality of these two components determines Glucosafe’s ability to safely lower BG. 
The model’s predictive accuracy can be tested and improved on retrospective data, 
but testing of the advice module in principle requires a clinical trial. To reduce the 
need for clinical trials, a method based on virtual patients was developed. The 
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virtual patients were based on insulin sensitivity profiles from real patients and 
were used to evaluate different settings of the penalty functions that govern 
Glucosafe’s treatment advice. An example showed how this method can be used to 
select settings of the penalty functions, likely to produce a desired outcome in terms 
of mean BG and frequency of hypoglycaemic events. Glucosafe with these 
modified settings may then be worthy of a new clinical trial.  
To improve the Glucosafe model’s ability to predict BG, a model of pancreatic 
insulin release was constructed. The pancreas model introduces a feedback loop in 
the Glucosafe model, which may produce instability. The model was found to be 
stable but also to produce damped oscillation after sudden changes in BG. An early 
version of the pancreas model showed a non-significant improvement in predictive 
accuracy, presumably because it was tested on critically ill patients with high BG 
and administration of large insulin doses. Further clinical testing is needed to 
investigate if the pancreas model improves predictive accuracy in patients who are 
recovering from critical illness. 
The literature on nutritional support for critically ill patients is still not in 
consensus. While there is support for not feeding the patient more than 100% of EE, 
as studies have shown this to have deleterious effects, some studies suggest 
targeting 100% of EE and some suggest targeting less. The hypothesis that the 
target should be 100% of EE stems from studies showing that a large caloric debt 
increases morbidity and/or mortality. Although there are studies advocating 
underfeeding patients, the American, European, and Canadian guidelines for the 
nutrition supports the hypothesis that nutritional support should target 100% of a 
patient’s EE to avoid or lessen caloric debt. With regards to restricting feeding in 
the first few days, there is no counter indication to the hypothesis that nutrition 
should be reduced in the first few days where the body catabolism provides the 
necessary substrates to cover energy needs. Regardless of the nutritional target 
being 100% of EE or less, an accurate estimation of a patient’s EE is needed. 
Predictive equations for estimating EE are not accurate and over- or underestimate 
patients’ EE compared to indirect calorimetry as shown in literature reviews and in 
the research presented in this thesis. VCO2-based calorimetry is the estimation of 
EE based on a patient’s VCO2, using a formula incorporating a Respiratory 
Quotient (RQ) value. The VCO2-based calorimetry results presented here show that 
VCO2-based calorimetry gives EE estimates significantly better than predictive 
equations. There are some problems in using only VCO2 as a measure for EE, as 
changes in ventilation which result in VCO2 not matching metabolically produced 
CO2, results in EE estimation errors lasting up to 20 min. due to the CO2 
equilibration time constant. Solutions to this is either the application of a running 
average of 5 min. or more to the measurements if the measurement period is short, 
or the use of the mean values from 24 hour measurements if possible. 
In conclusion there seems to be support for, or no direct evidence to oppose, the 6 
hypotheses stated.
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DANSK RESUME 
Stress induceret hyperglykæmi ses ofte i kritisk sygdom og er blevet associeret med 
øget morbiditet og mortalitet. Litteraturen om glykæmisk kontrol og ernæring er i et 
vist omfang modstridende, og der er ikke konsensus om optimale protokoller for 
behandling. Angående kontrol af blod glukose (BG) fremsætter denne afhandling 
hypoteser som siger at mortalitet kan reduceres ved at reducerer BG og/eller ved at 
reducerer frekvensen af hypoglykæmiske tilfælde. En yderligere hypotese er at i 
klinisk praksis er reduktionen af BG og hypoglykæmiske tilfælde bedst opnået ved 
brugen af model-baserede beslutningsstøtte systemer. Angående ernæring er det 
denne afhandlings hypotese, at der skal sigtes efter at administrere ernæring 
tilsvarende patientens energi forbrug (EE), undtagen i de første få dage efter skade, 
hvor der sigtes lavere end patientens EE. Afhandlingen hypoteserer også, at i 
klinisk praksis kan nøjagtig estimering af EE ikke udføres med prædikative 
ligninger, der anvender antropometriske data, men kan estimeres med en ny 
metode, CO2-baseret kalorimetri. Evidens fra litteratur, og de fire artikler som er 
basis for denne afhandling, bliver anvendt til at undersøge hver af de seks 
hypoteser. 
De fleste kontrollerede studies som anvender intensiv insulin terapi (IIT) har været 
succesfulde i at reducere BG men næsten alle resulterede i stigninger i antallet af 
patienter med hypoglykæmiske tilfælde. Studierne har vist forskellige resultater 
angående mortalitet, hvor ca. halvdelen af dem har resulteret i reduceret mortalitet 
og den anden halvdel har resulteret i øget mortalitet. Reduceret mortalitet var ikke 
associeret med reduktion i BG (p=0.40) eller med reduktion i procentdelen af 
patienter med alvorlig (BG > 2.2 mmol/l) hypoglykæmi (p=0.83). 
En todimensionel regressionsanalyse med ændringer i BG og hypoglykæmi som 
uafhængige variabler indikerede, at reduceret mortalitet var associeret med 
reduceret BG (p=0.05) og reduceret frekvens af hypoglykæmiske tilfælde (p=0.07). 
Dette støtter ideen, at hyperglykæmi burde reduceres, mens hypoglykæmiske 
tilfælde undgås. Kliniske studies understøtter hypotesen som siger at en reduktion 
af BG, uden hypoglykæmiske tilfælde, bedst opnås ved brugen af et model-baseret 
beslutningsstøttesystem. På trods af at der er mange forskellige sådanne systemer, 
både regel-baserede og model-baserede, har Glucosafe systemet (som anvender 
Glucosafe modellen), sammenlignet med andre systemer, vist enten større elle 
lignende reduktion i BG uden hypoglykæmiske tilfælde. 
Glucosafe har to overordnede komponenter: rådgivningsmodulet og modellen. 
Kvaliteten af disse to komponenter bestemmer Glucosafe’s evne til at sinke BG og 
undgå hypoglykæmi. Modellens prædiktive nøjagtighed kan testes og forbedres ved 
brug af retrospektiv data, men testning af rådgivningsmodulet kræver i princippet et 
klinisk studie. For at mindske nødvendigheden af kliniske studier blev en metode 
baseret på virtuelle patients udviklet. De virtuelle patienter var baseret på 
insulinsensitivitetsprofiler fra rigtige patients og blev anvendt til at evaluere 
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forskellige indstillinger af straffunktionerne, som styrer Glucosafe’s 
behandlingsrådgivning. Et eksempel viste, hvorledes denne metode kan anvendes til 
at vælge de indstillinger af straffefunktionerne, som sandsynligvis vil give et ønsket 
resultat, i form af gennemsnitlig BG og frekvens af hypoglykæmiske tilfælde. Med 
disse modificerede indstillinger vil det muligvis være fordelagtigt med et nyt klinisk 
studie af Glucosafe. 
For at kunne forbedre Glucosafemodellens evne til at prædiktere BG blev en model 
af insulinfrigivelse fra bugspytkirtlen konstrueret. Modellen introducerer et 
feedback-loop i Glucosafe modellen, hvilken kan give ustabilitet. Modellen fandtes 
at være stabil, men også at producere dæmpede oscillationer efter pludselige 
ændringer i BG. En tidlig udgave af bugspytkirtelmodellen viste en ikke signifikant 
forbedring i prædiktiv nøjagtighed, formentlig fordi den blev testet på kritisk syge 
patients med højt BG og indgift af store doser insulin. Ydereligere klinisk testning 
er nødvendigt for at undersøge om bugspytkirtelmodellen forbedre den prædiktive 
nøjagtighed hos patienter som er i bedring fra kritisk sygdom. 
Litteraturen om ernæring til kritisk syge er stadig ikke i konsensus. Mens der er 
støtte for ikke at ernære patienter mere en 100% af EE, da studier har vist, at det har 
en skadelig virkning, har nogle studier forslået at sigte efter 100% af EE og nogle 
har forslået at sigte lavere. Hypotesen om at målet skulle være 100% af EE stammer 
fra studier, der har vist at en større kaloriegæld øger morbiditet og/eller mortalitet. 
På trods af at der findes studier som advokerer for at underernære patienter, så 
støtter de amerikanske, europæiske, og canadiske retningslinjer for ernæring, 
hypotesen om at sigte efter 100% af EE for at undgå eller mindske kaloriegæld. 
Men hensyn til begrænset ernæring i de første dage er der ingen kontraindikation til 
hypotesen om at ernæring skal reduceres i de første dage, hvor kroppens 
katabolisme giver de nødvendige substrater til at dække kroppen energibehov. 
Uanset om ernæringsmålet er 100% af EE eller lavere, så er en nøjagtig estimering 
af patientens EE nødvendig. Prædiktive ligninger til at estimerer EE er ikke 
nøjagtige og over- eller undervurderer patienters EE sammenlignet med indirekte 
kalorimetri, som vist i litteraturgennemgange og i forskningsresultater præsenteret i 
denne afhandling. I VCO2-baseret kalorimetri er estimeringen af EE baseret på en 
patients VCO2, ved brug af en formel indeholdende en Respiratorisk Kvotient (RQ). 
Resultaterne viser at VCO2-baseret kalorimetri giver EE estimater signifikant bedre 
end prædiktive ligninger. Der er dog nogle problemer ved brugen af VCO2-baseret 
kalorimetri til estimering af EE, da ændringer i vejrtrækning kan resulterer i et 
VCO2 som ikke stemmer med den metaboliske producerede CO2, hvilket resulterer 
i EE estimationsfejl varende op til 20 min. grundet ligevægtstidskonstanten for 
CO2. Løsninger på dette er enten anvendelsen af et løbende gennemsnit på 5 min. 
eller mere, hvis måleperioden er kort, eller brugen af gennemsnitsværdier fra 24 
timers målinger, hvis det er muligt. 
Konklusionen er at der er støtte for, eller ingen beviser imod, de 6 fremsatte 
hypoteser.
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CHAPTER 1. INTRODUCTION 
 
1 
CHAPTER 1. INTRODUCTION 
Stress-induced hyperglycaemia commonly occurs during critical illness and has 
been associated with increased morbidity and mortality [1,2]. Treatment of 
hyperglycaemia by Intensive Insulin Therapy (IIT) has been shown to reduce 
mortality [3]. At the same time patients should receive adequate nutrition but both 
overfeeding and underfeeding with accumulation of large caloric debt has been 
shown to increase morbidity and or mortality [4,5].  
To some extent the results in the literature concerning glycaemic control and 
nutritional support are conflicting and do not provide consensus about optimal 
protocols neither for glycaemic control nor for nutrition. The six hypotheses 
formulated below reflect many of the issues currently discussed in the literature. In 
their actual formulation they also embed our view of what may be a reasonable 
interpretation of the literature.   
Concerning glycaemic control our hypotheses are that: 
G1: The mortality of the critically ill patient can be lowered by reducing average 
blood glucose (BG) to the upper end of the normal range  
G2: The mortality of the critically ill patient can be lowered by reducing the 
variability of BG and in particular reducing the incidence of hypoglycaemia 
G3: Reducing both BG and the incidence of hypoglycaemia is best achieved 
through the application of decision support systems based on physiological models 
Concerning nutritional support our hypotheses are that:  
N1: The nutritional support should target the patients’ Energy Expenditure (EE) 
without overfeeding  
N2: During the first few days of critical illness where catabolism dominates, the 
nutritional target should be less than the patient’s EE 
N3: The patient’s EE can be estimated with sufficient accuracy by a novel method, 
VCO2-based calorimetry, but not from predictive equations using anthropometric 
data. 
In the following chapters we seek to support the hypotheses through published 
literature and our own research. 
Chapter 2 provides an introduction to the physiology and pathophysiology of 
critical illness. The chapter also includes a review of the treatment of stress-induced 
hyperglycaemia and clinical studies of glycaemic control. The purpose is to provide 
a basis of knowledge for the rest of the thesis but also to support hypothesis G1, G2, 
N1, and N2. There have been studies which have shown reduced mortality when 
lowering hyperglycaemia towards normoglycaemia using insulin [3,6,7]. However 
some of these studies have resulted in increased hypoglycaemic events and have 
been criticized for this. 
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There have also been studies on how best to feed critically ill patients, however 
there is still some discussion as to the optimal nutritional strategy. In this chapter 
we examine the literature and seek to support our hypotheses on when and how 
much to feed the patients.  
Chapter 3 is based primarily on Paper I and introduces the concept of modelling. 
This includes a short review of different types of modelling, including physiological 
modelling, but primarily presents the Glucosafe model of insulin-glucose 
metabolism that is central to the work presented in this thesis. The purpose of this 
chapter is to show that decision support systems based on physiological models 
perform well compared to other forms of decision support, supporting hypothesis 
G3. This is done by examining some of the published models and decision support 
systems, evaluating how they preform, and comparing their performance with our 
own Glucosafe model and system. 
Chapter 4 is based primarily on Paper II and describes the development of a method 
to assess the likely treatment outcome of changes made to the advice module part of 
the Glucosafe system, without the need for a clinical trial. The chapter describes the 
use of virtual patients, based on real patients, to estimate treatment outcomes. If 
model-based decision support systems are to be the best tool to optimize treatment 
of critically ill patients then there needs to be a method of adapting the 
model/system to different patient cohorts. The purpose of this chapter is to present a 
method of adapting the Glucosafe system to offer optimal treatment advice for 
different patient cohorts or in line with different clinical guidelines. 
Chapter 5 is based primarily on Paper III and presents the work done to develop a 
model of pancreatic insulin release for the Glucosafe model. If the Glucosafe 
system is to prove hypothesis G3 correct it should be based on a model with 
physiologically correct assumptions. The Glucosafe model was initially not 
constructed to incorporate the variable insulin release from the pancreas, using 
instead a constant, fixed insulin release (as shown in chapter 3). The goal was to 
develop a model of pancreatic insulin release to improve the physiological 
correctness of the model and to possibly improve the model’s ability to predict BG 
and offer treatments advice.  
Chapter 6 is based primarily on Paper IV and presents work on optimizing patient 
nutrition in the ICU. In order to fulfil hypotheses N1 and N2 an accurate assessment 
of a patient’s nutritional needs is required as the question of how much to feed the 
patients is based on a patient’s EE, it becomes necessary to accurately estimate the 
EE. The work presented in chapter 6 is the work done to evaluate the accuracy with 
which a patient’s EE can be estimated and to support hypothesis N3, to present a 
simple and accurate method (VCO2-based calorimetry) to estimate EE using 
measurements of carbon dioxide production (VCO2). 
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CHAPTER 2. THE PATHOPHYSIOLOGY 
OF CRITICAL ILLNESS 
The human body controls the blood glucose balance using two negative feedback 
systems, insulin and glucagon. In the healthy person, if BG increases from 
normoglycaemia, the β-cells of the pancreas increase the release of insulin to the 
bloodstream to lower BG. If the BG concentration decreases from normoglycaemia, 
α-cells in the pancreas release glucagon in order to increase BG [8]. 
However in critical illness, the body’s response to injury results is, amongst others, 
the BG being increased despite the release of insulin. 
 
2.1. THE METABOLIC PHASES IN CRITICAL ILLNESS  
The body has a metabolic stress response to injury (be it from trauma, major 
surgery, burns, or sepsis). It involves a neuroendocrine and an immune component 
and includes increased catabolism and anabolism. Over time the body’s response to 
critical illness occurs in three phases: the acute phase and two more prolonged 
phases, the catabolic and the anabolic phases [9].  
 
2.1.1. THE ACUTE PHASE 
The first phase is the acute response, which often lasts <12 hours but in extreme 
cases up to 24 hours [9]. The patient develops the Systemic Inflammatory Response 
Syndrome (SIRS), which acutely is dominated by hemodynamic changes. Neurally 
mediated stress factors such as pain or hypovolemia activate the Hypothalamic-
Pituitary-Adrenal (HPA) axis. The hypothalamus releases corticotrophin-releasing 
hormone (CRH), which stimulates pituitary secretion of adrenocorticotropic 
hormone (ACTH).  Acutely, this results in increased adrenal secretion of 
epinephrine which in turn increases pancreatic glucagon production and suppresses 
the pancreatic insulin production when plasma epinephrine is above 2.2 nmol/l. 
This effect is powerful enough to inhibit insulin secretion despite hyperglycaemia 
[10,11]. In liver and muscles, the combination of high epinephrine and low insulin 
results in a rapid mobilization of the glycogen stores which in the liver is further 
enhanced by the elevated plasma glucagon concentration. This leads to elevated 
blood glucose, i.e. hyperglycaemia. 
In the muscles, the increased glycogenolysis (the breakdown of glycogen stores into 
glucose-6-P) increases the intracellular availability of glucose-6-P.  Oxidative 
metabolism is in the acute phase not elevated despite the availability of substrates. 
This is possibly due to lack of oxygen caused by reduced blood pressure [9]. 
Reduced blood pressure due to for instance hypovolemia is a common feature of 
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sepsis, severe burn and trauma. This means that glucose will be channelled through 
glycolysis and anaerobic lactic acid metabolism. The resulting lactate can diffuse 
out of the cell into the plasma, resulting in hyperlactatemia [9]. 
 
2.1.2. THE CATABOLIC PHASE 
The acute phase is followed by a catabolic phase, which, as the acute phase, is also 
dominated by SIRS, but with more metabolic than hemodynamic changes [12]. 
Through cytokines produced by immune cells [13] the HPA-axis is activated 
causing CRH-release from the hypothalamus which again stimulates pituitary 
ACTH secretion. In this phase, the hormonal response is different from the response 
in the acute phase as ACTH release leads to secretion of cortisol from the adrenal 
gland [14-17]. The plasma levels of epinephrine return to normal or near normal in 
the catabolic phase and only cortisol levels remain elevated throughout the 
catabolic phase [11]. The disappearance of the elevated epinephrine levels allows 
the pancreas to respond normally to hyperglycaemia, and therefore, due to the 
elevated blood glucose the patient enters a state of hyperinsulinaemia [11]. Insulin 
interacts with receptors in the cell membrane (primarily in skeletal muscles) 
triggering translocation of so-called GLUT-4 transporters to cell membranes, 
resulting in increased uptake of glucose. Insulin also induces the cells to store the 
glucose by converting it to glycogen and thus the increased glucose uptake and 
storage should result in the BG decreasing [18]. In general, the higher the BG the 
larger the insulin release, to a point where the pancreatic insulin release reaches a 
plateau. During times where BG is rising, the insulin release is also mediated by the 
rate of change in BG [8,19]. This physiological response is the basis of the 
modelling of a pancreatic insulin release model, shown in chapter 5.  
Both in the tissues and in the liver cortisol drives the catabolism. In the tissues, the 
catabolic effects of cortisol cause lysis of triglycerides into glycerol and free fatty 
acids (FFA). FFA can diffuse into the blood stream causing hyperlipidaemia [14]. 
In muscle tissues, cortisol also causes lysis of proteins into amino acids and hereby 
causes muscle wasting [20]. In both tissues and liver, cortisol causes 
glycogenolysis. Increased intracellular availability of glucose-6-P (from 
mobilization of the muscular glycogen stores due to cortisol and increased glucose 
uptake due to hyperinsulinaemia) results in hyperlactatemia as mitochondrial 
respiration cannot match the supply of glucose-6-P and therefore a large proportion 
may be metabolized anaerobically into lactate [10]. These catabolic effects 
counteract the anabolic effects of insulin, but during the catabolic phase it is 
apparent that the catabolism caused by cortisol is dominating: plasma levels of FFA 
rise [10], as do levels of amino acids [9,21]. BG also increases due to the increased 
concentration of glucagon and cortisol which return to normal 7-10 days after the 
initial injury [11,22]. Both glucagon and cortisol stimulates glycogenolysis, and 
gluconeogenesis (the synthesis of glucose from substrates such as fatty acids, 
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glycerol, lactate, and amino acids) [23]. The catabolism of proteins may cause 
substantial loss of muscle mass over the duration of the catabolic phase [24].  
 
2.1.3. THE ANABOLIC PHASE 
The catabolic phase overlaps with the anabolic phase and initially the elevated 
cortisol level keeps the catabolic response dominant. However as cortisol levels 
decrease so does the strength of the catabolic response. As the catabolic response 
lessens, the anabolic phase starts to dominate.  
The catabolic phase leaves the patient in a condition with an acute need for tissue 
repair due to the original insult and in addition a need for replenishing of the 
intracellular energy stores, which have been depleted by the catabolism. 
Presumably tissue repair has started already during the catabolic phase, such that 
there in reality is an overlap between the catabolic and anabolic phases – a situation 
where catabolism and anabolism coexist and the metabolism is increased. Thus 
tissue repair contributes to the duration of increased metabolism which typically 
lasts for a couple of weeks [25,26]. Often patients develop an energy debt during 
the first week of their stay in the intensive care unit due to slow progression to 
feeding target. The slow progression may be due to poor absorption by the patients 
of enteral nutrition, supplemented by fear of aspiration pneumonia or by cessations 
in feeding due to elective procedures [27]. This energy debt is mostly not 
compensated for during the latter part of the patient’s stay in the ICU and is 
correlated to worse clinical outcome [5,28].  
 
2.2. TREATMENT OF STRESS HYPERGLYCAEMIA 
As stated our hypotheses is that mortality can be lowered by reducing stress-
hyperglycaemia (G1) and by reducing hypoglycaemic events (G2). We also 
hypothesize that nutrition should target the patients’ EE (N1), except during the 
first few days of critical illness where the nutritional target should be less than the 
patient’s EE (N2). The support in the literature for G1 and G2 will be reviewed in 
section 2.2.1 and the support for N1 and N2 in section 2.2.2. 
 
2.2.1. GLYCAEMIC CONTROL WITH INSULIN THERAPY 
There have been several studies done using IIT to lower BG and investigating the 
effect on mortality. Studies have shown both reduced mortality and increased 
mortality, with most studies resulting in increased number of patients with 
hypoglycaemic events. This section reviews the studies and presents a regression 
analysis of the association between changes in mortality, BG and hypoglycaemia. 
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Studies with reduced mortality 
In 2001, in a landmark randomized controlled study (known as the Leuven study) of 
1548 critically ill patients (970 cardiac surgery patients and 578 non-cardiac 
surgery or trauma patients), Greet Van den Berghe et al. tested IIT to decrease 
hyperglycaemia in an attempt to reach normoglycaemia and reduce mortality. Using 
insulin infusions to target a BG concentration of 4.4 – 6.1 mmol/l, the study 
achieved a mean morning blood glucose of 5.7 mmol/l in the group receiving IIT, 
and 8.5 mmol/l in the conventionally treated control group. However the IIT 
resulted in 39 patients (5.1%) in the IIT group having severe hypoglycaemic events 
(BG < 2.2 mmol/l) compared to six patients (0.8%) in the control group. The 
reduction in hospital mortality was 9.5%, from 26.3% to 16.8%, a relative reduction 
in mortality of 45% [3].  
A second Leuven study in a medical ICU resulted in BG being lowered from 8.5 
mmol/l to 6.2 mmol/l but also a significant increase in patients with hypoglycaemic 
events (3.1% versus 18.7%) in the IIT group. The study showed no significant 
difference in mortality between the IIT group and the control group (28-day 
mortality of 29.9% versus 30.0%). 
There have been subsequent studies also showing reduced hospital mortality using 
IIT (see Table 2.1 for a summary of data from the studies).  
Krinsley et al. [6] showed a BG reduction from 8.5 mmol/l to 7.3 mmol/l with no 
significant increase in the percentage of patients with hypoglycaemic events 
(0.34%) compared to the historic controls (0.35%), and a 6.1% reduction in hospital 
mortality. 
Chase et al. [7] showed a reduction in BG (6.0 mmol/l in the intervention group and 
7.2 mmol/l in the retrospective comparison) with 5.2% of patients in the 
intervention group having hypoglycaemic events. The number of patients with 
hypoglycaemic events in the control group was not reported, but the study did show 
a modest but significant decrease in the number of hypoglycaemic measurements, 
from 0.2% of measurements in the control group to 0.1% in the intervention group. 
The study showed a 11.3% reduction in hospital mortality (in patients being in the 
ICU for 5 days or more) compared to historic controls. 
Arabi et al. showed a reduction in BG from 9.5 mmol/l to 6.4 mmol/l and despite a 
significant increase in patients with hypoglycaemic events (3.1% in the 
conventional treatment group versus 28.6% in the IIT group), showed a reduction in 
ICU mortality (17.1% in the conventional treatment group versus 13.5% in the IIT 
group). 
These studies indicate that lowering BG reduces hospital mortality, despite the 
failure in these studies to reduce hypoglycaemic events. This provides support for 
the G1 hypothesis. 
Studies with increased mortality 
However there have also been studies where IIT increased mortality: VISEP [29], 
NICE-SUGAR [30], Glucontrol [31], and a study by De La Rosa et al. [32]. All 
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resulted in lowered BG and increased number of patients with hypoglycaemic 
events, but increased mortality.  
The VISEP study was a multicentre, controlled two-by-two factorial trial, in 
patients with severe sepsis. The trial tested IIT versus conventional treatment and 
showed a reduction in BG from 8.4 mmol/l in the conventional treatment group to 
6.2 mmol/l in the IIT group. However the VISEP study was stopped early due to a 
large increase in the percentage of patients with hypoglycaemic events (17% vs. 
4.1%) and higher (10.9% vs. 5.2%) 90-day mortality in the IIT group.  
The NICE-SUGAR study randomized ICU patients into two groups, targeting a BG 
of 4.5 to 6.0 mmol/l in the intervention group and less than 10.0 mmol/l in the 
control group, resulting in a reduction in BG from 8.1 mmol/l to 6.6 mmol/l but an 
increase in patients with hypoglycaemic events (0.5% vs. 6.8%) and in 90-day 
mortality (24.9% vs. 27.5%). 
The Glucontrol study randomized ICU patients into two groups targeting a BG of 
either 4.4-6.1 mmol/l or 7.8-10-0 mmol/l and showed a BG reduction from 8.0 
mmol/l to 6.5 mmol/l but also an increase in patients with hypoglycaemic events 
(2.7% vs. 8.7%) and in 28-day mortality (15.3% vs. 18.7%). 
The De La Rosa study [32] reduced BG from 8.3 mmol/l to 6.7 mmol/l, but had an 
increase in patients with hypoglycaemic events (0.8% vs. 8.3%) and an increase in 
28-day mortality (32.4% vs. 36.6%). 
Regression analysis 
A linear regression analysis on how the reduction of BG (ΔBG) may reduce 
mortality (ΔMortality) shows no significant correlation (p=0.40). This shows that a 
conclusion on the effect of IIT on mortality cannot be drawn from the data on 
reduction of BG alone.  
A study by Preiser et al. [31] in a multi-centre trial with medical and surgical 
intensive care patients showed that the occurrence of hypoglycaemia coincided with 
a twofold increased risk of death independent of the blood glucose target range. 
Other studies [30,33] have also showed a similar association. These studies do not 
prove a causal connection between hypoglycaemic events and increased risk of 
death, but they are compatible with hypothesis G2: reducing hypoglycaemias 
reduces mortality. Table 2.1 shows that the studies with increases in mortality are 
also the studies with the largest increase in number of patients with hypoglycaemic 
events. A linear regression analysis between percentage of patients with severe (BG 
< 2.2 mmol/l) hypoglycaemia (ΔHypo) and mortality (ΔMortality) showed no 
significant correlation (p=0.83). 
To explore how a reduction in BG (ΔBG) and a reduction in the percentage of 
patients with severe (BG < 2.2 mmol/l) hypoglycaemia (ΔHypo) may reduce 
mortality (ΔMortality) a two-dimensional linear regression model was formulated: 
∆Mortality =  a ∙ ∆BG + b ∙ ∆Hypo Eq. 2.1 
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The regression was performed on the data in Table 2.1, which gave the resulting 
regression equation (SPSS, 23.0.0.0):  
∆Mortality =  3.2 ∙ ∆BG + 0.51 ∙ ∆Hypo Eq. 2.2 
with the p-values of a and b being 0.05 and 0.07, respectively. 
 
Table 2.1 Reduction in mortality, BG, and percentage of patients with severe 
hypoglycaemia (BG < 2.2 mmol/l) in the IIT group versus the control group. 
Study ΔBG 
(mmol/l) 
ΔHypo 
(BG<2.2 mmol/l) 
ΔMortality 
(%) 
Residuals 
Leuven 2.8 -4.3 9.5 -2.2 
Leuven-2 2.3 -15.6 0.1 -0.5 
Krinsley 1.2 0.0 6.1 -1.9 
SPRINT
a
 1.2 5.2 11.3 -4.3 
Arabi et al. 3.1 -25.5 3.6 -6.7 
VISEP 2.2 -12.9 -4.3 4.9 
NICE-SUGAR 1.6 -6.3 -2.6 4.6 
Glucontrol 1.5 -6.0 -3.4 5.2 
De La Rosa et al. 1.6 -7.5 -4.2 5.7 
Mean (SD) 1.9 (0.7) -8.1 (9.0) 1.8 (6.1) 0.6 (4.7) 
a
 The number of patients in the control group with hypoglycaemic events was not 
reported, but the percentage of hypoglycaemic measurements was twice that of the 
intervention group. For the purpose of this regression we therefore assumed that 
10.4% of patients in the control group had hypoglycaemic events, twice that of the 
intervention group. 
Despite the a and b values in the regression formula being a little less than 
significant, the regression does lend some support to both the G1 and G2 hypothesis 
that lowering stress-hyperglycaemia improves patient care in terms of lowering 
mortality, in so far as hypoglycaemic events are avoided or not increased to a large 
degree. G2 is further supported by studies [34,35] which have shown that BG 
variability is a strong predictor of hospital mortality. 
 
2.3. ENSURING ADEQUATE CALORIC INTAKE 
American, European, and Canadian guidelines for the nutrition of critically ill 
patients recommend eucaloric feeding, i.e. that the caloric intake should match the 
individual patient’s EE [36-38], based on studies which have shown that 
overfeeding by as little as 10% relative to EE can adversely affect organ function, 
leading to e.g. hypercapnia, metabolic acidosis, and fatty liver [4]. It has also been 
shown that in critically ill patients, a high caloric debt, calculated as the difference 
between caloric intake and the patient’s actual EE, is associated with an increased 
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rate of adverse outcome in terms of increased number of infections [5]. This 
supports our N1 hypothesis, that nutrition should target 100% of patient’s EE. 
Despite the negative effects of caloric debt, the guidelines are more flexible 
concerning underfeeding than overfeeding, by allowing delayed initiation of enteral 
feeding by 24 hours [37] or by 24-48 hours [36,38] and by recommending a seven 
day delay in initiation of parenteral feeding in case the nutritional target cannot be 
achieved by enteral feeding alone [36]. This acceptance of a delay of supplementary 
parenteral nutrition may be justified by the observation that early parenteral feeding 
increases the rate of infection [39] but contrasts with the desire to avoid a large 
caloric debt. 
There is still some disagreement on the subject of whether or not to underfeed the 
patients and whether to initiate early feeding or late feeding of the patients. Arabi et 
al. showed that hypocaloric feeding (approximately 60% of EE) may be associated 
with lower hospital mortality [40]. Artinian et al [41] and Khalid et al. [42] both 
showed that initiation of enteral nutrition within 48 hours of mechanical ventilation 
was associated with reduced ICU and hospital mortality. While the nutritional 
guidelines support our N1 hypothesis on eucaloric feeding and no overfeeding, 
there are studies [40,43] which suggest permissive underfeeding as optimal and that 
the early use of parenteral nutrition should be avoided. It is intuitively appealing to 
restrict caloric intake in the catabolic phase where plasma concentrations of 
glucose, lipids and amino acids is already high. It may be however that the 
detrimental effects of early parenteral nutrition does not reflect negatively on 
parenteral nutrition but on the fact that the early parenteral nutrition results in early 
eucaloric feeding which according to our hypothesis (N2) should be avoided, 
although more evidence from randomized trial is still needed to properly support 
the hypothesis. 
 
MODEL-BASED DECISION SUPPORT FOR NUTRITION AND INSULIN TREATMENT  
OF HYPERGLYCAEMIA IN THE ICU 
 
10 
  
CHAPTER 3. DECISION SUPPORT SYSTEMS FOR GLYCAEMIC CONTROL 
11 
CHAPTER 3. DECISION SUPPORT 
SYSTEMS FOR GLYCAEMIC CONTROL 
Decision support systems have been developed to assist medical staff with the 
management of stress induced hyperglycaemia, while avoiding hypoglycaemia, in 
critically ill patients. These decision support systems have ranged from rule-based 
systems and protocols, to complex physiological mathematical models. It is our 
hypothesis, G3, that the use of decision support systems based on physiological 
models is the best method for glycaemic control. 
This chapter is based primarily on Paper I which describes the Glucosafe decision 
support system. In addition this chapter contains descriptions of physiological 
models and decision support systems, including a comparison of systems. 
 
3.1. TYPES OF DECISION SUPPORT SYSTEMS 
3.1.1. RULE BASED SYSTEMS 
These systems are also known as expert systems as the rules used are often set by 
experts in the field [44]. A type of rule based protocol is the sliding scale system 
which administers a set a predetermined amount of insulin at different ranges of BG 
(e.g. 1U/h if BG is 6-8 mmol/l and 2U/h if BG is 8-9 mmol/l). Another type is the 
dynamic scale which adjusts the insulin dosage by a predetermined size of change 
depending on the range the BG is in (e.g. if BG is 6-8 mmol/l the insulin is 
increased by 1U/h, if BG is 8-9mmol/l the insulin is increased by 2U/h).  
Examples of rule based systems include the SPRINT system [7], which developed a 
set of rules based on simulations with a physiological model. Examples also include 
the eProtocol-insulin system which uses a set of rules to determine the rate of 
insulin infusion: For BG < 3.3mmol/l the rules state that the insulin infusion is 
discontinued. For BG ≥ 3.3mmol/l the insulin infusion rate is adjusted based on the 
difference between the BG target (set by clinicians) and the current BG, modulated 
by the rate of change in BG between the current and previous BG measurement. 
[45]. In section 3.4 the rule-based eProtocol-insulin system is compared to the 
Glucosafe system, which is based on a physiological model. 
 
3.1.2. PHYSIOLOGICAL MODELS  
In physiological models it is attempted to let the structure of the model reflect the 
physiology of the biological system being modelled. The majority of these systems 
have been based on compartmental models of insulin-glucose metabolism, using 
differential equations [44].  
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Perhaps the best known physiological model is the minimal model by Bergman et 
al. which was constructed with two compartments for insulin pharmacokinetics and 
an equation for insulin-glucose pharmacodynamics [46,47].  
dX
dt
= −p2X(t) + p3(I(t) − Ib) Eq. 3.1 
dG
dt
= −X(t)G(t) + p1(Gb − G(t)) + P(t) Eq. 3.2 
G(t) is the plasma glucose concentration at time t, I(t) is the plasma insulin 
concentration, and X(t) is the interstitial insulin. Gb is the basal plasma glucose 
concentration, P(t) is the appearance rate of glucose from exogenous input and Ib is 
the basal plasma insulin concentration. Patient specific parameters p1, p2 and p3 are 
transport rates between the various compartments with the ratio p3/p2 representing 
insulin sensitivity. 
The minimal model captures the three basics of models for glycaemic control; 1) 
insulin pharmacokinetics and distribution, 2) Glucose appearance, and 3) the effect 
of insulin on removal of plasma glucose.  
Most compartment models used for studies of glycaemic control have their basis in 
the minimal model, with compartments or equations added as necessary to improve 
the patient specific simulation and prediction of BG [48]. This has led to increases 
in physiological accuracy of the models [48]. 
A more complex model was developed by Hovorka et al [49] for the purpose of 
controlling type-1 diabetes. The model was multi-compartmental and included 
subsystems for insulin and glucose absorption, including subcutaneous insulin 
absorption, distribution, and disposal, as well as insulin action on glucose transport, 
disposal and endogenous insulin production. The model was designed to control 
insulin delivery in artificial pancreas systems. There are other models [50,51] 
developed for use in artificial pancreas systems [52]. 
Based on the minimal model but further incorporating saturation effect of plasma 
insulin disappearance and insulin-dependent glucose uptake a model was developed 
by Chase et al. and further developed into the Intensive Control Insulin-Nutrition-
Glucose (ICING) model [53]. Like the Hovorka et al. model, the ICING model 
incorporates insulin and glucose absorption, distribution, and disposal, as well as 
insulin action on glucose transport and endogenous insulin production. However the 
ICING model was constructed for use in the ICU with intravenous insulin delivery, 
not subcutaneous boluses. 
Prior to the development of the Hovorka et al. model and the ICING model, the 
Diabetes Insulin Advisory System (DIAS) model [54], was constructed to predict 
BG and advice on insulin dosing to manage type-1 diabetes. The DIAS model was 
constructed to model the uptake of glucose from the intestines, facilitated diffusion 
of glucose mediated by glucose transporters (GLUT-1, GLUT-3, and GLUT-4), and 
renal clearance of glucose. The DIAS model was constructed to incorporate insulin 
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saturation effects and included a patient specific parameter to model the effects of 
insulin sensitivity [55]. The DIAS model parameters were optimized using 
literature data on hepatic and endogenous glucose balance. From the DIAS model a 
multi-compartment model of insulin-glucose metabolism was constructed, the 
Glucosafe model [56]. The Glucosafe model is similar to the DIAS model but uses 
a more explicit compartment model of plasma and peripheral insulin concentrations 
and removal. And like DIAS the Glucosafe model incorporates the modelling of the 
non-linear effect of insulin on glucose uptake, but also models reduced gastric 
uptake of glucose and (as shown in chapter 5) now includes a model of pancreatic 
insulin secretion. 
The chosen focus of this thesis is the Glucosafe model and the Glucosafe system 
incorporating the model. 
 
3.1.3. MODEL PREDICTIVE CONTROL 
Decision support systems for insulin therapy based on physiological mathematical 
models can be used to predict the outcome of a treatment. By simulating several 
treatments, the treatment resulting in the optimal outcome can be recommended to 
the decision maker. In the context of glycaemic control, the simulations are 
performed using a model of the insulin-glucose metabolism with the input 
parameters being current and previous insulin treatment, nutritional status, and BG 
measurements.  
There are several methods to evaluate model output and adjust input where the 
model is used to generate an output, based on an input. One method is the 
proportional-integral-derivative (PID) control where the output is compared to a 
predetermined target output and the input is changed based on the difference 
between output and target. However PID control has several limitations to its use. 
The use of PID control presupposes linearity and, as the input is adjusted based on 
the output, has only a single input and a single output. Less restrictive is the Model 
Predictive Control (MPC) [44], where the output is compared to a predetermined 
target output and the input is adjusted stepwise until the model output matches the 
target. An example would be adjusting the insulin infusion rate until the resulting 
BG matches a predetermined target.  However MCP is limited by only being able to 
evaluate the outputs of the model relative to a set target and then optimize the 
output by changing the input. MCP however is not capable of optimizing both 
inputs and outputs or compromising between several targets. 
One method to manage multiple inputs and outputs (such as both insulin and 
nutrition inputs influencing the simulated BG) or having multiple objectives to 
resolve (such as wanting to lower BG to a specific target while also targeting a 
certain nutritional goal, for example  100% of a patients energy expenditure), is the 
use of utilities. Utilities can take the form of a set of equations used to evaluate both 
input and output and finding the best compromise between multiple objectives. 
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The Glucosafe system, incorporating the Glucosafe model, uses (negative) utilities 
in the form of a set of penalty functions to control the generation of treatment 
advice [57]. The penalty functions balance the administration of insulin and 
nutrition in an attempt to compromise between achieving normoglycaemia while 
neither starving nor overfeeding the patient.  
 
3.2. THE GLUCOSAFE MODEL 
The Glucosafe decision support system is based on the Glucosafe model [56] of 
insulin-glucose metabolism. The model and equations are shown in Fig. 3-1.  
The Glucosafe model uses a two-compartment insulin kinetics model to simulate 
plasma insulin (I) and peripheral insulin (Q) concentrations. This is based on the 
endogenous production (U) and exogenous infusions (P) of insulin and the removal 
of insulin by the kidneys and by insulin degradation in the liver and peripheral 
tissue. In Glucosafe the pancreatic insulin release is a constant rate, unless the 
patient is a type-1 diabetic in which case the insulin release is zero. 
The insulin sensitivity (s) scales the effect of insulin (a) on hepatic removal and 
peripheral absorption of glucose. The insulin sensitivity is a dimensionless 
normalized parameter so a value of one indicates normal insulin sensitivity and 
values below one indicate insulin resistance. In the model the estimated insulin 
sensitivity is assumed to be a time-varying, patient-specific parameter, which is 
independent of the treatment the patient is receiving.  
The Glucosafe model takes patient height, weight, age, and gender into account to 
determine patient-specific parameters such as distribution volumes. Following the 
initial determination of patient-specific parameters, the variables gut content, 
plasma and interstitial insulin concentrations, and BG are continually modelled 
based on user specified inputs (i.e. BG measurements, insulin dosing, and amount 
and composition of nutrition), however the only parameter used to fit the model to 
the data (i.e. BG measurements) is the insulin sensitivity which is re-estimated 
every time a new BG measurement is input to the system, thus making it the only 
patient specific parameter allowed to vary over time. 
The simulated BG concentration is a model variable that depends on insulin-
mediated and insulin-independent glucose clearance from plasma and glucose 
uptake from intravenous infusions and carbohydrate uptake from nutrition. The 
insulin-mediated glucose clearance is affected by the non-linear insulin saturation 
function [56], and the uptake of bioavailable glucose from nutrition is scaled by a 
carbohydrate absorption factor (mgut) to model reduced nutrient absorption in 
critical illness. The C-peptide/insulin kinetics parameters; k1, ABSA, VP, and VQ are 
calculated using the method presented by Van Cauter et al. [58] and the moving 
average function, f(.), for renal clearance is taken from Rave et al. [59]. Further 
information on parameters, variables, and values can be found in [56]. 
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Figure 3-1 The Glucosafe model of insulin-glucose metabolism. Solid lines indicate 
flows and dashed lines indicate effects of variables or parameters on other 
variables. 
 
3.2.1. VALIDITY OF THE GLUCOSAFE MODEL 
To determine the validity of the model it can be tested for the ability to predict 
future BG concentration. This is done retrospectively using data on nutrition, 
insulin, and BG from patient, by having the model predict BG from one real 
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measurement to the next, for all measurements and all patients used. The predictive 
accuracy is then calculated. The relative error, e(Δtik), is calculated as: 
e(Δtik) = |
m(ti + Δtik) − G(ti; Δtik)
m(ti + Δtik)
| Eq. 3.3 
Δtik =  ti+k − ti Eq. 3.4 
∀i|1 ≤ i ≤ N − 1 Eq. 3.5 
∀k|Δtik < PH Eq. 3.6 
N is the total number of BG measurements for the patient, PH is the prediction 
horizon (i.e. the maximum forward prediction time the prediction error is to be 
calculated for), Δtik is the time between two BG measurements (ti and ti+k), G(ti;Δtik) 
is the model-predicted blood glucose from time point ti and Δtik forward, and m(ti + 
Δtik) is the measured BG value at Δtik time from ti. Note that the prediction error is 
expected to increase with longer prediction times. Thus, the individual errors are 
sorted by Δtik in ascending order, and the absolute mean prediction error is 
calculated for two intervals of t: (1) 1 min ≤ Δtik ≤ 90 min; (2) 91min ≤ Δtik ≤ 
180min. 
The result of testing the predictive accuracy on a cohort of 12 critically ill patients 
in a neuro-ortho-trauma intensive care unit (NOTIA) at Aalborg University 
Hospital in Denmark [60] was a mean prediction error of 8.7% (1-90 min.) and 
13.9% (91-180 min.). The total mean prediction error (0-180 min.) was 11.9%.  
 
The Glucosafe model had its predictive accuracy tested and compared to a paper-
based protocol from Christchurch, New Zealand [61]. Both were tested on 
retrospective patient data from two cohorts, one from Denmark and one from New 
Zealand. 
The results showed very similar predictive accuracy, with the Christchurch protocol 
more accurately predicting the New Zealand patients and the Glucosafe model more 
accurately predicting the patients from Denmark. 
 
3.3. THE GLUCOSAFE SYSTEM 
The Glucosafe system uses the Glucosafe model to simulate a patient and from 
there, predict the patient’s future BG. The main control window of the Glucosafe 
system is shown in Fig. 3-2. 
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Figure 3-2 The main control screen of the Glucosafe system with a window on the 
left hand side displaying measured and predicted BG, current and previous insulin 
infusions and nutrition. On the right hand side of the screen is information on the 
patients and the current treatment and several boxes for inputting changes to the 
current and previous treatment and BG measurements. At the bottom of the right 
hand side are buttons for requesting treatment advice and accepting, modifying, or 
rejecting the advice. 
 
3.3.1. TREATMENT ADVICE 
Advice is shown upon user request, typically after a new blood glucose 
measurement. Upon a request for advice, the model predicts the blood glucose 
trajectory for different treatments consisting of a continuous insulin infusion rate 
(or insulin infusion rate and bolus size if the BG is above ten mmol/l) and either an 
enteral feed rate, an intravenous feed rate, or a combination of the two feed types. A 
penalty score rates the tested treatments and the treatment with the lowest penalty 
score is deemed the optimal treatment and is shown to the user. Users can either 
accept or reject the advice, or modify it (Fig. 3-2). In case of a modification the user 
overrules the advice manually, setting one or both of the recommended feed rates 
(enteral and intravenous) and asking for new advice based on these settings. If both 
feed rates have been manually set by the user, Glucosafe adjusts only the insulin to 
minimize the penalty score, and recommends only insulin along with the user 
specified nutrition. 
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As previously mentioned, Glucosafe uses a set of four penalty functions which 
evaluate the treatment objectives to determine the optimal treatment advice. Fig. 3-
3 shows plots of the penalty functions used in the Glucosafe system. 
Glycaemic Penalty – The penalty increases for treatments which result in the 
predicted BG above or below the target. The penalty increases more rapidly for BG 
concentrations that are below the target, in order to minimize the occurrence of 
hypoglycaemia. The BG target (G0) can be set by the user. The penalty (Fig. 3-3A) 
is defined as:  
fG(G) =  (ln (
G
G0
))
2
× PG Eq. 3.7 
where G is the predicted BG, G0is the specific BG where the penalty is zero [62] 
(standard setting is 5.5 mmol/l), and  PG = 22. 6 is a dimensionless scaling factor. 
The BG penalty used is the mean of penalties calculated from the predicted BG at 
one, two, three, and four hours. 
Insulin Consumption Penalty – To decrease the use of excessive insulin, the use is 
penalized with the following function (Fig 3-3B): 
fI(P) =  (
(P × C + Km)
2
Km
2 − 1) × PI Eq. 3.8 
where P is the insulin infusion rate (mU/(kg×min.), C = 98.1 kg/min.×L is a factor 
for converting insulin infusion rate to steady state plasma concentrations [55], 
Km = 28 mU/L is a Michaelis-Menten saturation constant [63], and PI = 0.00916 is 
a dimensionless scaling factor. 
Mucosal Damage Penalty – To maintain functional intestinal mucosa, the amount of 
nutrition administered enterally is maximized using the following function (Fig. 3-
3C): 
fD = (Nenteral − 1)
2 × PD Eq. 3.9 
where Nenteral is the fraction of the EE that is administered enterally and PD = 1 is 
a dimensionless scaling factor. EE is the caloric intake needed to cover 100% of the 
patient’s energy expenditure.  
Nourishment Penalty – In Glucosafe the EE of the patient is estimated using the 
Mifflin St Jeor equation based on height, weight, age, and gender, multiplied by a 
user selected Stress Factor (SF) to accommodate the hypermetabolism usually seen 
in the critically ill. The following function (Fig. 3-3D) is used to penalize under- or 
over-feeding relative to the estimated EE: 
fC(Ntotal) = (Ntotal − 1)
2 × PN Eq. 3.10 
where Ntotal is the total nutrition administered, as a percentage of EE, and PN = 1 is 
a dimensionless scaling factor. The values of the scaling factors shown here are 
different from those previously published [57], though the ratio between them are 
the same. This is because the values here have been normalized so that PD and PN 
are equal to one. 
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The dimensionless scaling factors used in the four equations were derived by a 
simulation of steady state BG from combinations of insulin and nutrition, over a 
range on insulin sensitivities. From there a treatment target was set for each insulin 
sensitivity and then minimizing the sum of squares of the difference between 
Glucosafe advice and the set advice targets [57]. 
A grid search of the possible treatment combinations of insulin and nutrition is used 
to minimize the sum of these penalties and the treatment advice on nutrition and 
insulin resulting in the lowest combined penalty is shown to the user.  
Figure 3-3 The four penalty functions used by the Glucosafe system to determine the 
treatments advice resulting in the lowest combined penalty. 
 
3.4. PERFORMANCE OF THE GLUCOSAFE SYSTEM 
To examine if our hypothesis (G3) that decision support systems based on 
physiological models is the best method to lower hyperglycaemia while avoiding 
hypoglycaemic events the Glucosafe system has been tested in three different 
clinical studies (including Paper I of this thesis, which this chapter is based upon) 
and compared to other models and systems. Glucosafe is compared to both other 
computer based systems and paper based systems, some of which are model-based 
and some of which are not. 
As seen from Table 3.1, the Glucosafe system has, in all three clinical trials, been 
able to lower BG without any hypoglycaemic events.  
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Table 3.1. Comparison of glucose control trials. Above the thick line are 
trials using computer-based decision support, below the line are paper 
based trials. 
 BG (mmol/l) 
Mean (SD) 
Median (IQR) 
Patients with hypoglycaemia 
Mild (BG < 3.3 mmol/l)
 
Severe (BG < 2.2 mmol/l) 
Trial Intervention Control Intervention Control 
Glucosafe 1 [60] 7.0 (± 1.2) 
7.1 (6.3-7.9) 
8.0 (± 1.2) 
8.0 (7.0-9.1) 
0.0% 
0.0% 
0.0% 
0.0% 
Glucosafe 2 [62] 7.0 (± 1.1) 
7.2 (6.6-8.2)
a
 
8.6 (± 2.4) 
8.0 (6.9-6.9)
a
 
0.0% 
0.0% 
0.0% 
0.0% 
Glucosafe 3 [64] 5.8 (± 1.0)
a
 
5.6 (5.0-6.6) 
7.8 (± 1.8)
a
 
7.8 (6.6-8.7)
a
 
0.0% 
0.0% 
0.0% 
0.0% 
LOGIC-1 [65] 5.9 (± 0.5) -- 14.1% 
0.0% 
17.9% 
3.3% 
STAR-Liege 2 
[66] 
-- 
7.4 (6.5-8.4) 
-- 
8.6 (6.9-9.5) 
0.0% 
0.0% 
0.0% 
0.0% 
Leuven 1 [3] 5.7 (±1.0) 
-- 
8.5 (± 1.8) 
-- 
-- 
5.1% 
-- 
0.8% 
SPRINT [7] 6.0 (±1.5) 
-- 
7.2 (± 2.4) 
-- 
-- 
5.2% 
-- 
-- 
Glucontrol [31] -- 
6.5 (6.0-7.2) 
-- 
8.0 (7.1–9.0) 
-- 
8.7% 
-- 
2.7% 
NICE-SUGAR 
[30] 
6.6 (± 1.4) 
-- 
-- 
-- 
74.2% 
6.8% 
15.8% 
0.5% 
Krinsley [6] 7.3 (±3.1) 
6.6 (5.5-8.2) 
 1.02% 
0.34% 
 
a
 Unpublished data 
Table 3.1 shows a comparison of Glucosafe and two other trials using computer 
based systems, the LOGIC-1 trial and the STAR-liege 2 trial. While the LOGIC-1 
trial achieved lower BG than two of the Glucosafe trials it also had 14.1% of 
patients experiencing mild hypoglycaemic events (defined as BG < 3.3 mmol/l). 
The STAR-Liege-2 trial avoided hypoglycaemic events but was inferior to 
Glucosafe in terms of lowering BG. This indicates that Glucosafe performs better 
than the other computer-based systems in terms of lowering BG while avoiding 
hypoglycaemic events. 
With reference to hypothesis G3, that model-based systems are better able to lower 
hyperglycaemia while avoiding hypoglycaemia, Table 3.1 clearly indicates this, as 
all the trials using paper-based systems show the occurrence of hypoglycaemic 
events. Further support to the hypothesis is a direct comparison of Glucosafe and 
the rule-based eProtocol-insulin system [45]. The Glucosafe system consistently 
provided more favourable recommendations on insulin use based on data from 408 
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critically ill patients treated using the eProtocol-insulin system, supporting 
hypothesis G3. 
Overall Glucosafe has shown the ability to lower BG while avoiding any 
hypoglycaemic events. The Glucosafe 3 study was the most successful in lowering 
BG, reaching BG concentrations similar to the Leuven 1 study (5.7 mmol/l), but 
where the Leuven study had 5.1% of patients with hypoglycaemic events, the 
Glucosafe 3 study had no hypoglycaemic events. That the third Glucosafe study 
achieved lower BG than the previous two Glucosafe studies is most likely because 
the patients were fed very little, some only receiving intravenous glucose, and as 
Glucosafe was not allowed to advise on nutrition the patients continued to receive 
little nutrition when treated with Glucosafe. 
These studies evaluating the Glucosafe system, and the comparison to other studies, 
supports our hypothesis (G3) that the use of physiological models and decision 
support systems can be beneficial in glycaemic control and a better tool than non-
model based systems. However if model-based decision support systems are to be 
the best tool to optimize treatment of critically ill patients then there needs to be a 
method of adapting the model/system to different patient cohorts. 
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CHAPTER 4. EVALUATING 
MODIFICATIONS TO THE GLUCOSAFE 
SYSTEM 
Glucosafe has two major components: the model and the advice module. As 
previously mentioned the Glucosafe model can be (and has been) evaluated by 
determining its predictive accuracy, i.e. its ability to minimize the distance between 
predicted and measured blood glucose concentrations. This can be done from 
retrospectively collected data and the effects of modifications to the model can 
conveniently be tested by evaluating the modified model on the same retrospective 
data. Evaluation of the Glucosafe system’s ability to control BG (i.e. how good is 
the advice offered by Glucosafe) is more complicated. This is (and has been) done 
by conducting a clinical trial, where the Glucosafe system is allowed to recommend 
insulin and nutrition to a patient cohort and then determining the performance of the 
system on this cohort in terms of the clinical goals for blood glucose, nutrition, and 
insulin. 
As stated in chapter 2, hyperglycaemia is treated using insulin to lower the BG. 
While Glucosafe has been shown to reduce hyperglycaemia in clinical trials 
[60,62], in two of those studies the goal of reducing the mean BG into the target 
band of 4.4 – 6.1 mmol/l was not achieved, even though  G0 in the glucose penalty 
function was set to 5.5 mmol/l (section 3.3.1, Eq. 3.7). This happens because the 
Glucosafe advice minimizes the sum of all four penalty functions, which 
necessitates compromises in each of the four penalty functions. For example, 
increasing the insulin dosing will lower the BG, thus simultaneous reducing the BG 
penalty and increasing the insulin consumption penalty. If the user of Glucosafe 
actually prefers to reduce BG, even at the expense of a higher insulin consumption 
penalty, this can practically be achieved by changing the balance between the two 
penalties, for example by scaling down the insulin consumption penalty. Since there 
are four interacting penalty functions, finding out which modifications to make to 
the penalty functions to achieve a specific treatment target, in order to optimize the 
treatment of a patient cohort or to best accommodate department guidelines, could 
be problematic as this would require further clinical trials which are expensive and 
time consuming. The purpose of this chapter is to describe a method for adjusting 
the relative scaling of the penalty functions without clinical trials. The chapter is 
primarily based on Paper II, though with some results omitted for brevity. 
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4.1. VIRTUAL PATIENTS 
It is possible to test and compare the outcome of changes to the advice generator 
using virtual patients constructed from actual patients treated by Glucosafe.  
Virtual patients have been used in the design and testing of IIT protocols [67,68]. 
Others have developed them for evaluating type-1 diabetes treatments [69,70] and 
in critical care [71].  
As previously mentioned a study using Glucosafe in an ICU achieved a 
significantly lower BG compared to the control group (see Table 3.1, Glucosafe 1). 
However the study failed to achieve the targeted 4.4 – 6.1 mmol/l BG range [60]. 
As an example of how the virtual patients can be used to select settings of the 
penalty functions likely to produce a desired outcome in terms of mean BG and 
frequency of hypoglycaemic events, several modifications to the penalty functions 
were tested to find the settings resulting in a mean BG in the 4.4 – 6.1 mmol/l 
range. The virtual patients were constructed from six patients treated according to 
Glucosafe advice (intervention group) and six control subjects from the previously 
mentioned study [60]. The virtual patients were constructed with the same model 
and penalty functions as used during the clinical study.  
 
4.2. VIRTUAL PATIENTS AND THE GLUCOSAFE SYSTEM 
The virtual patients are based on insulin sensitivity profiles from patients previously 
treated using Glucosafe. The profiles are generated from the insulin sensitivity 
estimated for every BG measurement entered into the Glucosafe system. As the 
insulin sensitivity is assumed to be independent of the treatment the patient is 
receiving it can be used to describe a specific patient’s insulin responsiveness over 
time. An example of an insulin sensitivity profile is given in Fig. 4-1, where insulin 
sensitivity is recalculated whenever a new blood glucose measurement is entered 
into the Glucosafe system. 
Figure 4-1 Example of a 14 hour insulin sensitivity profile from a patient.  
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Figure 4-2 Diagram of the 
Glucosafe system when used 
for advice generation with real 
patients and when used for 
testing with virtual patients. 
Insulin sensitivity is estimated 
by Glucosafe during real-time 
use, based on the patient’s 
measured BG and the amount 
of nutrition and insulin the 
patient has been receiving. 
The insulin sensitivity 
estimated during real patient 
use is then forced upon the 
system during virtual patient 
generation. 
Fig. 4-2 shows a diagram of Glucosafe when used in real-time with patients and 
when using virtual patients. In real-time, an amount of insulin and nutrition is given 
to the patient with a resulting measured BG. The measured BG and administered 
insulin and nutrition amounts are used by the Glucosafe model to estimate the 
insulin sensitivity at that specific time. As previously mentioned, a grid search of 
the possible treatment combinations of insulin and nutrition, and the resulting 
predicted BG four hours ahead, is input into the penalty functions, to generate an 
advice for new insulin and nutrition amounts.  
In the virtual patient the insulin sensitivity profile previously estimated from the 
real patient is used by the Glucosafe model to simulate BG during subsequent 
testing. With the insulin sensitivities read from the insulin sensitivity profile, a 
single BG measurement from the patient is used as a starting point and Glucosafe is 
asked for an advice on insulin and nutrition. The advice is followed and at the time-
point for the next BG measurement, the BG predicted by the model is used instead 
of the measured BG. Using the predicted BG as a starting point the insulin 
sensitivity is read from the insulin sensitivity profile, and a new advice is requested.  
This method results in a cohort of virtual patients, based on real patients, where 
model predicted BG is used in lieu of measured BG, and as the insulin sensitivity 
profile is meant as a profile of patient behaviour independent of treatment, the 
treatment advice given by Glucosafe is what determines the patients BG over time. 
This means that different settings for the penalty function governing advice 
generation can be compared by analysing the outcome of the virtual patient cohort, 
e.g. the mean BG, or which settings result in a desired treatment outcome.  
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4.3. EVALUATING MODIFICATIONS USING VIRTUAL 
PATIENTS 
A patient cohort was managed with Glucosafe [60] with the penalty function 
settings listed in section 3.3.1, (G0 = 5.5 mmol/l) seeking to reduce the cohort mean 
BG to between 4.4 and 6.1 mmol/l. A mean BG of 7.0 mmol/l was achieved. 
Several different modifications were made to the penalty functions which govern 
treatment advice and then the modifications were tested for their influence on 
glycaemic control on the set of virtual patients derived from the cohort. The 
purpose of testing several modifications was to determine which set of 
modifications was required to achieve a mean BG between 4.4 and 6.1 mmol/l in 
the cohort of virtual patients. 
The following modifications were tested: 
Glycaemic Penalty – The BG where the penalty is zero (G0), was lowered from 5.5 
mmol/L to 5.25 mmol/L, which is the middle of the 4.4 – 6.1 mmol/l band. This 
results in higher penalties for BG above the target (Fig. 4-3A). 
 
Figure 4-3 The penalty functions used in the Glucosafe system to find the treatment 
advice. The solid lines are the original penalty functions. The dashed lines are the 
modified penalty functions. 
Insulin Consumption Penalty – Two different changes were made to the insulin 
dose penalty function by lowering PI (section 3.3.1, Eq. 3.8) with a factor of two 
and ten (Fig. 4-3B).  
Mucosal Damage Penalty – The function was modified to be raised to the sixth 
power instead of the second power: 
fD = (Nenteral − 1)
6 × PD Eq. 4.1 
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This changes the shape and overall lowers the Mucosal Damage Penalty (Fig. 4-
3C). 
Nourishment penalty – PN (section 3.3.1, Eq. 3.10) was reduced by a factor of two 
which lowers the penalty for over and underfeeding the patient (Fig. 4-3D). 
 
4.4. RESULTS 
As the use of virtual patients rests on the assumption that the underlying model is 
sufficiently accurate in predicting BG, first the real and virtual patients were 
compared in order to validate the virtual patients. This was done by determining if 
virtual patients, using the same treatment advice setting as used on the real patients, 
would result in a similar outcome in terms of BG, insulin use, and nutrition. There 
were some deviations between the virtual patients and the real patients, primarily 
due to the real patients having cessations of insulin and nutrition administration that 
the virtual patients did not replicate. Despite this there were no significant 
differences between the real and the virtual patients in insulin use or nutrition nor in 
the log-normally distributed BG. As such, all 12 virtual patients were deemed 
usable to evaluate modifications. The virtual patient cohort had a mean BG of 6.5 
mmol/l before any modifications were tested. Modifying the penalty functions gave 
the results: 
 Lowering G0 to 5.25 mmol/l reduced BG to 6.3 mmol/l. 
 Reducing the insulin dose penalty by a factor of 2 had no impact on BG; 
reducing the insulin dose penalty by a factor 10 lowered BG to 6.4 mmol/l.  
 Reducing the mucosal damage penalty lowered BG to 6.3 mmol/l. 
 Reducing the nourishment penalty lowered BG to 6.4 mmol/l. 
As none of the modifications tested resulted in decreasing the BG for the cohort 
into the 4.4-6.1 mmol/l band, combinations of modifications were tested.  
The full results of the accuracy testing and the results of the individual 
modifications can be found in Paper II. 
The modifications of the penalty functions were evaluated by comparing results 
from the 12 virtual patients before and after the modifications. The biggest effects 
on mean BG were seen by lowering the glycaemic target and by lowering the 
mucosal damage and nourishment penalties. Combining these three modifications 
resulted in a mean BG of 5.9 mmol/l for the cohort with 54% of BG measurements 
in the target BG band, compared to 39% without any modifications. The 
consequence was a lowering of the administered nutrition (from 79% to 60% of 
estimated EE) and a 0.6 U/h decrease in insulin usage, from 5.4 U/h to 4.8 U/h. The 
combined modifications resulted in a mean BG of 5.9 mmol/l, which is within the 
4.4-6.1 mmol/l band, with seven of the twelve virtual patients having a mean BG in 
the band.  
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This compares well with the Leuven study [3] which achieved a mean BG of 5.7 
mmol/l, considering that the study reported only morning BG which has been 
shown to be lower than BG measured later in the day [72]. 
The lowest BG in the virtual patient cohort was 3.6 mmol/l reduced to 3.3 mmol/l 
with the combined modifications. Using the definitions of hypoglycaemia from 
Table 3.1, this measurement touches the limit of mild hypoglycaemia. There were 
no events of severe hypoglycaemia compared to the 5% of patients (39 out of 765 
patients) in the Leuven study which experienced hypoglycaemic events. 
The results show that the use of virtual patients as a tool, is suited to optimize 
treatment in a clinical study after an initial pilot study or as a tool to continually 
optimize treatment in a clinical setting, although it will remain necessary to verify 
in a new set of real patients that the proposed modifications of the advice algorithm 
produce similar results in real patients as in virtual patients.  
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CHAPTER 5. MODELLING 
PANCREATIC INSULIN RELEASE 
The Glucosafe model has previously been tested for accuracy and performed well, 
both in clinical trial and while testing the accuracy of the virtual patients. However 
as mentioned, the cornerstone of the usability of virtual patients is the predictive 
accuracy of the underlying model and while Glucosafe may perform well in its 
current configuration, it does not model pancreatic insulin release other than as a 
constant release. 
The body’s own method of managing hyperglycaemia is by releasing variable 
amounts of insulin from the pancreas, and the relationship between BG and 
pancreatic insulin secretion is complex. In the Glucosafe model the pancreatic 
insulin release was modelled as a constant release regardless of the patient’s BG 
concentration [56]. This was not a problem as the patients treated with Glucosafe 
had high BG’s resulting in a high and almost constant endogenous insulin release. 
However if Glucosafe is to model patients during their recovery phase, where they 
may have lower BG, a model of BG dependent insulin release must be included. To 
do this a model of pancreatic insulin release was constructed. This chapter gives the 
results from Paper III, with some results omitted for brevity. 
 
5.1. PANCREATIC INSULIN RELEASE 
The pancreas model was based partly on previous studies and models of pancreatic 
insulin release. Cerasi and Luft [19] found a dual-phase insulin release (i.e. a phase-
1 and phase-2 response) in healthy humans during glucose infusion tests and Porte 
and Pupo [73] found evidence of a two-pool insulin system. 
Their findings indicate that pancreatic insulin release is a dual-compartment, dual-
phase process, with the phase-1 insulin response being dependent on the rate of rise 
of BG (dBG/dt) and the phase-2 response being dependent on the BG 
concentration, in a sigmoidal relationship. 
There have previously been constructed models of insulin secretion; Grodsky [74] 
built a model of pancreatic insulin secretion with two insulin compartments. The 
compartments were modelled with a larger stable compartment containing 98% of 
the stored insulin and a smaller labile compartment containing 2% of the stored 
insulin. Transport between the compartments was governed by the BG with insulin 
secretion occurring from the labile compartment only. Hovorka et al. [75] also 
constructed (as part of a model of glucose regulation) a model of insulin secretion. 
Like the Grodsky model, the model by Hovorka et al. only modelled the phase-2 
response, using a linear relationship between BG and endogenous insulin release.  
Inclusion of a pancreatic model with insulin release being dependent on BG, creates 
a negative feedback loop. In any system, a feedback loop with an absolute value of 
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the loop gain (|LG|) larger than one has the potential to make the system unstable, 
resulting in oscillations or damped oscillations. While neither the Grodsky nor the 
Hovorka model was tested for stability, Steil et al. [76] performed stability tests 
with models of insulin secretion by combining them with a one-compartment 
insulin kinetics model and a minimal model of glucose kinetics [47].  
Previous Glucosafe simulations with a pancreas model with only a phase-2 
response, showed that if the BG of a person with normal insulin sensitivity was 
perturbed by a glucose injection over a 10 min. period, then BG and insulin release 
responded by a damped oscillation [77].  
If a pancreas model is to be included in the Glucosafe model, then it needs to be 
stable before any testing of prediction accuracy can be performed. Thus further 
testing was performed on the inclusion of a pancreas model in the Glucosafe 
system, evaluating the stability of Glucosafe with a dual-phase, dual compartment, 
pancreas model including both a phase-1 and phase-2 response (the Phase 1+2 
model). 
 
5.2. THE PANCREAS MODEL 
The new pancreas Phase 1+2 model, incorporated into the Glucosafe model, is 
shown in Fig. 5-1, with the pancreas model highlighted in red.  
The total endogenous insulin release is both the phase-1 (P1) and phase-2 (P2) 
response with the exception of type-1 diabetes patients, where endogenous insulin 
production is assumed to be zero. 
The phase-1 response is proportional to the rate of change of BG, and to the amount 
of insulin in insulin reservoir 2 (R2). K2 is a constant. 
The phase-2 response is a sigmoid curve that describes the rate of endogenous 
insulin release as a non-linear dependency on the BG concentration, BG(t). The 
sigmoid relationship between BG and insulin secretion has been shown 
experimentally by Henquin et al. [78].  
The curve was fitted to the data shown in Fig. 5-3. The negative insulin release 
modelled at low BG concentrations is not indicative of negative insulin release, but 
can be seen as a glucagon release as this has the effect of increasing BG. R1max and 
R2max are the maximum contents of the respective reservoirs and Rtotal is the 
maximum amount of stored insulin. As in the Grodsky model [74], R1max and R2max 
limits the maximum content of compartments R1 and R2 to 98% and 2% of Rtotal, 
respectively. 
With this model the endogenous insulin production is dependent on the BG through 
a negative feedback loop. An increase in BG results in increasing endogenous 
insulin production that counteracts the rise in BG. 
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Figure 5-1 The Glucosafe model of insulin-glucose metabolism, including the model 
of pancreatic insulin release (marked in red). Solid lines indicate flows and dashed 
lines indicate effects of variables or parameters on other variables. The model 
differs from the model in Fig. 3-1 with the addition of the pancreas model which 
changes the insulin release (U) from a constant to being determined by P1 and P2 
as shown (i.e. dependent on BG concentration and rate of change in BG). 
 
 
 
 
Figure 5-2 The phase-2 
response of the pancreas 
model, illustrating the sigmoid 
relationship between BG and 
insulin secretion. The equation 
for the phase-2 response curve 
is shown in Fig. 5-1 (P2) 
where epmin and epmax are 
asymptotes to P2(t) and 
together with S, determine the 
slope at BGhalf.  Parameter 
values are shown in Table 5.1. 
 
 
5.3. TESTING THE PANCREAS MODEL 
The pancreas model was fitted to BG and plasma insulin data from 14 healthy 
adults (mean age 38.5 ±3.7, mean weight 70.1 kg), using a grid search programmed 
in Matlab. The subjects received three meals over the course of one day, and 
Polonsky et al. [79,80] collected 58 BG and plasma insulin measurements from 
each subject over a 24 hour period. The mean values of the BG and plasma insulin 
measurements from the 14 subjects were used to optimize the shape of the sigmoid 
curve (phase-2), the magnitude of the phase-1 response (K2), the dependence of 
insulin movement from R1 to R2 on BG (K1), and Rtotal. Using the BG changes from 
the data, the resulting plasma insulin calculated by Glucosafe was compared to the 
mean values from the patient data and the model was fitted to minimize the Root 
Mean Square Error (RMSE) between the 58 measured and modelled plasma insulin 
concentrations. 
 
5.3.1. LOOP GAIN 
The steady-state loop gain of Glucosafe with each of the two pancreas models was 
calculated in the following manner: 
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(1) Using either insulin infusions or intravenous glucose infusions a specific 
steady-state BG0 was obtained and the steady-state endogenous insulin 
production U0 was noted. 
(2) A new steady-state endogenous production rate (U0 + ε) with ε = U0/10 
was set as a fixed insulin release and the steady-state BG and the resulting 
endogenous insulin production (U0 + δ) was simulated. 
(3) The loop gain was then calculated as: LG = |δ/ε|. 
 
5.3.2. POST-PERTURBATION OSCILLATIONS 
At the BG resulting in the largest loop gain, and thus where the model is potentially 
the least stable, the model was tested for the occurrence of oscillations in BG and 
insulin secretion following an initial perturbation of BG (post-perturbation 
oscillations). The post-perturbation oscillations were examined for two insulin 
sensitivities representing the “insulin-resistant” state and the “insulin-normal” state. 
For the “insulin-resistant” state a reduced insulin sensitivity of 0.3 was chosen as is 
often seen in critically ill patients [77]. For the “insulin-normal” state a value of 1.0 
for insulin sensitivity was chosen. The perturbation was an intravenous glucose 
infusion over ten min. resulting in a one mmol/l increase in BG. The subsequent 
oscillations in BG and endogenous insulin production were simulated by the 
Glucosafe model and described by the period and the time constant (τ) for the decay 
of the oscillations. 
 
5.4. RESULTS 
5.4.1. FITTED MODEL PARAMETERS 
The plasma insulin data from the healthy subjects and the fitted pancreas model can 
be seen in Fig. 5-3.  
The fitting of the pancreas model to plasma insulin data resulted in parameter 
values as shown in Table 5.1. 
Table 5.1. Fitted parameter values for the Phase 2 and 
Phase 1+2 models 
Parameter Value Unit 
Phase 1+2 model 
epmin -3.9 mU/min. 
epmax 42 mU/min. 
BGhalf 6.1 mmol/l 
S 1.3 mU/min.∙(mmol/l)
-1
 
K1 0.0009 l∙mmol
-1
∙min.
-1
 
K2 0.57 l∙mmol
-1
 
Rtotal 16800 mU 
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Figure 5-3. 24-hour profile of mean BG and mean plasma insulin concentrations 
from 14 healthy subjects receiving meals [79], and the plasma insulin 
concentrations simulated with the Glucosafe model using the optimized Phase 1+2 
pancreas model. Figure adapted from [81]. 
 
5.4.2. LOOP GAIN RESULTS 
The loop gain of the phase 1+2 model was calculated for steady state BG 
concentrations of 3.0 mmol/l to 10 mmol/l, for the two different levels of insulin 
sensitivity. The maximal LG with an insulin sensitivity of 0.3 was 4.0 at a BG of 
6.3 mmol/l and with an insulin sensitivity of 1.0 the maximal loop gain was 6.6 at a 
BG of 6.0 mmol/l. Fig. 5-4 shows the change in loop gain for the model. 
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Figure 5-4 Calculated loop gain at different pairs of steady state blood glucose and 
insulin sensitivity. Figure adapted from [81]. 
 
5.4.3. POST PERTURBATION OSCILLATIONS 
As the maximal loop gain (i.e. where the model is potentially most unstable) was 
observed at a steady state BG of 6.0 mmol/l and an insulin sensitivity of 1.0, the 
model was tested for post perturbation oscillations from that steady state BG. The 
result was an occurrence of damped oscillations. Fig. 5-5 shows a comparison of 
the post-perturbations oscillations in BG and insulin release for the model (with an 
insulin sensitivity of 1.0 and 0.3). 
The damping of post-perturbation BG oscillations was described by fitting an 
exponential function to the envelope of the first two oscillations. Using the 
following equation:  
E(t) = −1.30 mmol/l ∙ exp
−t
40 min.⁄ + 6.0 mmol/l Eq. 5.1 
The time constant τ of the envelope was 40 min. for the pancreas model, at a normal 
insulin sensitivity of 1.0. The envelope is plotted along with the post perturbation 
BG oscillations in Fig. 5-5. 
As seen in Fig. 5-5, the BG perturbation resulted in damped oscillations, but despite 
a loop gain greater than one, the pancreas model proved stable with a time-constant 
of the damping of 40 min.  In Paper III the model shown here was compared to a 
model with only a phase-2 response. The Phase 2 model resulted in longer lasting 
oscillations compared to the Phase 1+2 model shown here and had an envelope time 
constant of 92 min.  
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Figure 5-5 Post-perturbation curves for blood glucose (A with insulin sensitivity of 
1.0 and C with insulin sensitivity of 0.3) and (B) endogenous insulin release for the 
Phase 1+2 pancreas model with insulin sensitivity of 1.0. The thinner line (A) is the 
envelope fitted to the first two oscillations. The initial perturbation was a one 
mmol/l increase in BG over ten min., from a steady state BG of 6.0 mmol/l. Figure 
adapted from [81]. 
What remains to be investigated is to which extent the Phase-1+2 model improves 
the accuracy of BG predictions. In Paper I [60] an early version of the Phase 2 
model was tested for improvement in predictive accuracy compared to a constant 
insulin release. The result was only a marginal improvement, likely because the 
patient cohort was critically ill and over 60% had a BG above 7 mmol/l and thus 
there was little difference between the constant release and the phase-2 release. As 
stated in the beginning of this chapter the Phase 1+2 model is expected to improve 
predictive accuracy of the Glucosafe system in patients with lower BG. 
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CHAPTER 6. ENERGY EXPENDITURE 
IN THE ICU 
Glucosafe has thus far been constructed to offer advice on insulin and nutrition in 
order to achieve normoglycaemia in critically ill patients. The system has been 
tested for its ability to lower BG and has proven that capability and using virtual 
patients has shown the possibility of achieving normoglycaemia in a patient cohort, 
through increased insulin usage and a decrease in the amount of nutrition 
administered. As stated previously, Glucosafe estimates the EE of the patient using 
the Mifflin St Jeor equation, multiplied by a user selected SF. However if Glucosafe 
is to offer advice on nutrition then the estimation of EE should be accurate. With 
regard to hypothesis N1 and N2 of this thesis, studies have shown that overfeeding 
by as little as 10% relative to actual EE can adversely affect organ function, leading 
to e.g. hypercapnia, metabolic acidosis, and fatty liver [4] and conversely a high 
caloric debt, calculated as the difference between caloric intake and the patient’s 
actual EE, has been associated with a high rate of complications and adverse 
outcome [5]. If the goal is not to overfeed the patient (N1) and in the first day of 
critical illness not to feed the patient 100% of EE (N2), then the EE needs to be 
accurately determined. The N3 hypothesis states that predictive equations cannot 
accurately determine EE but that VCO2-based calorimetry can. To test this 
hypothesis some commonly used predictive equations and the VCO2-based 
calorimetry is compared to indirect calorimetry (IC) measurements and the results 
compared to other results from literature.   
 
6.1. DETERMINATION OF ENERGY EXPENDITURE 
The determination of a patient’s EE can aid clinicians when they prescribe nutrition 
as caloric needs differ from person to person and with type (sepsis, trauma/surgery, 
burns) of insult [25,26,82]. The reference method to determine EE is IC [83], which 
estimates EE using measurements of oxygen consumption (VO2) and VCO2. 
However, the use of IC is limited both by cost of equipment and by demand on 
resources (e.g. time, equipment and staff) [84,85].  
The use of a caloric intake based on EE determined by predictive equations is 
recommended when IC cannot be used. However reviews by Tatucu-Babet et al. 
[86] and Frankenfield et al. [87] of the extensive body of literature, which compares 
various predictive equations to IC, conclude that predictive equations are often 
inaccurate. Both reviews found that 12% of the reviewed predictive equations 
overestimated EE by more than 10% and underestimation was even more frequent 
with 38% of the equations underestimating EE by more than 10%. Most of the 
studies evaluating the Harris-Benedict equation use an SF ranging from 1.13 to 1.6. 
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This large range of SF may partially be due to interindividual differences, but also 
to systematic variations of SF due to the severity and type (sepsis, trauma/surgery, 
burns) of insult [25,26,82] as well as the time elapsed since the insult [25,26].  
Hence, there is a need for an accurate and easy method to estimate EE, as it can 
help clinicians prescribe caloric intake during the late phase of critical illness [88]. 
A possible suitable option is the calculation of EE from VCO2 alone, “VCO2-based 
calorimetry”, routinely measured by capnometers connected to the ventilatory 
circuit in mechanically ventilated patients [89]. VCO2-based calorimetry has 
previously been tested using a modified Weir equation [90], to make the EE 
estimation dependent on VCO2 and the Respiratory quotient (RQ) and then 
individualized by estimating the patient RQ from nutritional intake [91,92]. 
As there is evidence that both over- and under-feeding is harmful, accurate 
determination of EE becomes vital, if Glucosafe is to offer nutritional advice. 
However the predictive equation Glucosafe uses may not be accurate in estimating 
EE. As such there are two questions relevant to hypothesis N3:  
1) Can the poor performance of predictive EE equations be confirmed in our cohort 
of patients?  
2) Can the estimation of EE be based on VCO2? 
 
6.2. COMPARISON OF PREDICTIVE EQUATIONS, VCO2-
BASED CALORIMETRY, AND INDIRECT 
CALORIMETRY 
As IC is considered the reference method for estimating EE, the predictive 
equations and the VCO2-based calorimetry, were compared to IC measurements. 
Both IC and VCO2-based calorimetry rely on the assumption that the rates of 
ventilated O2 and CO2 reflect the rate of O2 consumption and CO2 production, 
respectively. However, EE(IC) and EE(VCO2) calculated from instantaneous values 
of VO2 and VCO2 may be erroneous in situations where respiratory VO2 and VCO2 
are not equal to the metabolically consumed O2 or produced CO2, respectively. 
Therefore VCO2-based calorimetry and IC was assessed for possible sources of 
error in EE estimation, both qualitatively and quantitatively, and as VCO2-based 
calorimetry is based on the choice of an RQ value, a sensitivity analysis was 
performed. 
The comparison was performed using measurements from patients at a mixed 
medical/post-surgical ICU at Erasme University Hospital of Brussels, Belgium. 
Eighteen mechanically ventilated patients, 18 years or older, were included as soon 
as possible after ICU admission. Height, gender, body mass, temperature, diagnosis, 
mode of ventilation, APACHE 2 score at admission [93], and mode of sedation 
were recorded. VO2, VCO2, End Tidal CO2 (ET-CO2), Fraction of inspired O2 
(FiO2), Minute Volume (MV), and RQ were measured over a 30-min. period. The 
metabolic monitor used was a Compact Airway Module, E-CAiOVX mounted in a 
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Compact Anaesthesia Monitor (GE Healthcare, Little Chalfont, Buckinghamshire, 
UK), which offers breath-by-breath VCO2 and VO2 measurements [94]. The 
Compact Airway Module determines VCO2 and VO2 within ±10% when FiO2 < 
65% [95].  
EE was determined, using the Weir equation (3): 
EE(IC)=(5.5 min/ml ∙ VO2 + 1.76 min/ml ∙ VCO2 − 1.99 day/g ∙ N) kcal/day Eq. 6.1 
with a standard setting of N = 13 g/day [95], as ureic nitrogen was not measured in 
the study, yielding: 
EE(IC) = (5.5 min/ml ∙ VO2 + 1.76 min/ml ∙ VCO2 − 26) kcal/day Eq. 6.2 
In this study this was used as the reference method, against which other EE 
estimates were compared.  
 
6.2.1. PREDICTIVE EQUATIONS AND VCO2-BASED 
CALORIMETRY 
The equation for estimating EE based on VCO2 was constructed from Eq. 6.2, with 
VO2 substituted by: 
VO2 = VCO2 RQ⁄  Eq. 6.3 
This gives the modified Weir equation: 
EE(VCO2) = ((5.5 min ml⁄ ∙ RQ
−1 + 1.76 min ml⁄ ) ∙ VCO2 − 26)kcal/day Eq. 6.4 
VCO2 measurements used in the EE(IC) and EE(VCO2) estimations are both 
derived from the metabolic monitor. Differences between EE(IC) and EE(VCO2) 
must either be due to an incorrect assumption about RQ or due to variations in 
ventilation. Variations in ventilation will cause different variations in EE(IC) and 
EE(VCO2) because the time constant for VCO2 equilibration is much longer (10-20 
min.) [96,97] than the time constant for VO2 equilibration (2-3 min.) [98]. 
The accuracy of the EE(VCO2) estimates and of some commonly used predictive 
equations (Table 6.1) were compared to EE(IC).  
The value of SF, used for the cohort with the Harris-Benedict equation (b, Table 
6.1) was calculated using the following equation: 
SF = mean EE(IC) / mean EE(HB) Eq. 6.5 
The SF for methods c and d (Table 6.1) were similarly determined using their 
respective mean EE. The result is that the mean EE for the 18 patients determined 
by each method equals the mean EE(IC) determined by Eq. 6.2 (the reference 
method).  
The ideal body mass (IBM) was calculated from the Hamwi equations [99]: 
Men: IBM = 48.0 kg + 2.7 kg  (height – 1.524 m) / 0,0254 m Eq. 6.6 
Women: IBM = 45.5 kg + 2.2 kg  (height – 1.524 m) / 0.0254 m Eq. 6.7 
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Table 6.1: Predictive equations for estimation of EE 
 Method Equation 
a ACCP 
The ACCP equation [36-38] using BM as the only variable 
EE(ACCP) = 25 kcal/kg/day · BM 
b 
Harris-
Benedict 
 
The Harris-Benedict equation from 1919 [100] multiplied by a SF 
Men: EE(HB) = (66.5 + 13.75 kg
-1
 · BM + 5.003 cm
-1
 · height - 6.775 
yr
-1
  · age) kcal/day · SF 
Women: EE(HB) = (655.1 + 9.563 kg
-1
 · BM + 1.85 cm
-1
 · height - 
4.676 yr
-1
  · age) kcal/day · SF 
c 
Harris-
Benedict 
IBM   
The Harris-Benedict equation with ideal body mass (IBM) multiplied 
by a SF 
Men: EE(HBI) = (66.5 + 13.75 kg
-1
 · IBM + 5.003 cm
-1
 · height - 
6.775 yr
-1
  · age) kcal/day · SF 
Women: EE(HBI) = (655.1 + 9.563 kg
-1
 · IBM + 1.85 cm
-1
 · height - 
4.676 yr
-1
  · age) kcal/day · SF  
d 
Mifflin 
St Jeor  
The Mifflin St Jeor equation [101] multiplied by a SF 
Men: EE(MSJ) = (9.99 kg
-1
  BM + 6.25 cm
-1
  height - 4.92 yr
-1
  age 
+ 166) kcal/day · SF 
Women: EE(MSJ) = (9.99 kg
-1
  BM + 6.25 cm
-1
  height - 4.92 yr
-1
   
age – 161) kcal/day · SF 
e 
Penn 
State 1 
The original Penn State equation from 1998 [102] 
EE(PS1) = 1.1·HB + (32 min·l
-1
· MV + 140 C
-1
·TMax – 5340) 
kcal/day 
f 
Penn 
State 2 
Version 2 of the Penn State equation from 2003 [103] 
EE(PS2) = 0.85·HB + (33 min·l
-1
·MV + 175 C
-1
·TMax – 6433) 
kcal/day 
g 
Penn 
State 3 
Version 3 of the Penn State equation from 2003 [103] 
EE(PS3) = 0.96·MSJ + (31 min·l
-1
·MV + 167 C
-1
·TMax – 6212) 
kcal/day 
ACCP: American College of Chest Physicians, TMax: Maximum body temperature 
in 24 hours [°C]. 
 
6.2.2. STATISTICAL ANALYSIS 
To assess the bias of each method (the predictive equations and EE(VCO2)), the 
difference in percent between mean EE for the method and mean EE(IC) was 
calculated. The significance was tested by a two-tailed paired t-test. The assumption 
of normal distribution of tested variables was assessed with the Shapiro-Wilk test. 
RMSE was used to describe the quality of the predictions for each method. A 
comparison of EE(VCO2) and each predictive equation was performed by an F-test 
over the prediction errors relative to EE(IC). 
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To determine the how often the methods resulted in accurate predictions of EE, the 
number of patients with accurate predictions was compared between EE(VCO2) and 
each predictive equation, with per-patient EE estimates defined as accurate if the 
estimate was within ±10% of the IC measurement. Testing for significant 
differences was performed using Fisher’s exact test. Significance level for all tests 
was p < 0.05.  
 
6.2.3. SENSITIVITY ANALYSIS OF RQ 
The practical use of VCO2-based calorimetry relies on a choice of RQ. A sensitivity 
study of the effect of the choice of RQ was conducted. In six studies [82,103-108] 
the average reported cohort values for RQ ranged from 0.76 to 0.89. These 
minimum and maximum values and the extreme range of the physiological range 
(0.7 to 1.0) [92] were used in the sensitivity analysis.   
 
6.2.4. QUALITATIVE ANALYSIS OF DYNAMIC ERRORS 
As mentioned both IC and VCO2-based calorimetry rely on the assumption that the 
rate of ventilated O2 and CO2 is reflecting the rate of O2 consumption and CO2 
production, respectively. A mismatch however may occur when the patient’s 
metabolism changes rapidly, or due to changes in the patient’s ventilation. The 
VCO2-based calorimetry should only be used if the patients EE is constant over the 
measurement period. To determine if a patient had constant EE, the trend line for 
the VO2 recording was compared with the average VO2 over the recording period. 
If the absolute difference between the trend line and the average was less than 10% 
of the average VO2, the patient was considered to have constant EE throughout the 
recording period.  
From the patients with constant EE, an example patient was selected and a 
descriptive analysis of the reasons for errors was performed by inspection of the 30 
min. recordings of MV, VCO2, VO2, and ET-CO2 and comparing these to the 
changes in EE(IC), and EE(VCO2). 
Quantitative analysis of dynamic errors  
As the EE(IC) and EE(VCO2) estimation may be affected by changes in ventilation, 
the two methods’ vulnerability to changes in ventilation was analyzed and 
compared. For each patient the maximum deviation of EE from the mean EE was 
calculated for both EE(IC) and EE(VCO2). The effect of a five min. moving 
average on the calculated EE was explored by comparing the maximum EE 
deviations from mean EE, for both EE(IC) and EE(VCO2), before and after its 
application. 
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6.3. RESULTS 
The 18 patients included had a mean age 61±17 years, five were women. Average 
VO2 for the 18 patients was 343±77 ml/min. and average VCO2 was 273±63 
ml/min, giving an average RQ of 0.81. The mean FiO2 was 42% with no patient 
exceeding 50%. All patients received intravenous glucose during the measurement 
period and patients 1, 2, 3, 14, 17, and 18 received enteral nutrition. The mean RQ 
for the patients receiving enteral nutrition (0.86) was significantly higher (p<0.05; t-
test, unpaired, two-tailed) than the mean RQ (0.79) for the patients not receiving 
enteral nutrition.  Individual patient specifics can be found in Paper IV upon which 
this chapter is based [109]. 
Table 6.2. Comparison of EE estimates to IC including sensitivity of 
EE(VCO2) reliance on RQ. 
The bias in percent is relative to the mean EE(IC). The range of estimation 
differences is the maximum and minimum difference between the equations and 
individual mean EE(IC). The RMSE of EE difference is the root mean square error 
of EE difference between the equations and the IC measurements. Accurate EE 
estimates are defined as per-patient EE within ±10% of EE(IC). 
Equation Mean EE  
(Bias) 
kcal/day 
Range of 
estimation 
differences 
RMSE of 
EE 
difference 
# of patients with 
accurate EE 
estimates (%) 
ACCP 1889 (-20%)* [-49 %; 22 %] 28 %† 6 (33 %)‡ 
Harris-Benedict 2347 (0%) [-20 %; 61 %] 16 %† 9 (50%)‡ 
Harris-Benedict, IBM 2347 (0%) [-23 %; 76 %] 18 %† 8 (35 %)‡ 
Mifflin St Jeor  2347 (0%) [-18 %; 68 %] 15 %† 9 (50 %)‡ 
Penn State 1 1782 (-24%)* [-41 %; 0 %] 27 %† 1 (6 %)‡ 
Penn State 2 1572 (-33%)* [-49 %; -10%] 35 %† 1 (6 %)‡ 
Penn State 3 1637 (-30%)* [-43 %; -9%] 32 %† 1 (6 %)‡ 
EE(VCO2) RQ=0,81 2332 (-1%) [-13 %; 14 %] 7 % 16 (89 %) 
EE(IC) 2347 (0%) - - - 
Sensitivity analysis of RQ 
EE(VCO2) RQ=0,70 2626 (12%)* [-2 %; 30 %] 12 % 9 (50 %)‡ 
EE(VCO2) RQ=0,76 2455 (5%)* [-8 %; 20 %] 8 % 14 (78 %) 
EE(VCO2) RQ=0,85 2244 (-4%) [-16 %; 10 %] 6 % 16 (89 %) 
EE(VCO2) RQ=0,89 2163 (-8%)* [-19 %; 6 %] 10 % 10 (56 %) 
EE(VCO2) RQ=1,00 1976 (-16%)* [-26 %; -3 %] 17 % 4 (22 %)‡ 
* Significantly different from mean EE(IC).  
† Significantly greater variance than EE(VCO2) RQ=0.81.  
‡ Significantly different from EE(VCO2) RQ=0.81. 
All predictive equations, a through g, largely over- and underestimated the 
reference EE value (see Fig. 6-1). The Penn State equation and the ACCP equation 
had the largest bias, while the ranges of estimation difference were largest for the 
ACCP, Harris-Benedict, and Mifflin St Jeor equations (Table 6.2). The SF values 
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used in the Harris-Benedict (1.55 for actual body mass, 1.67 for IBM) and Mifflin 
St Jeor (1.59) equations resulted in these equations having no bias, but the quality 
of prediction was poor for all predictive equations, as shown by a 15% or greater 
RMSE. The accuracy was also poor for all predictive equations with all of them 
having 50% or less of patients with accurate EE estimates.  
The EE(VCO2) was significantly better than the predictive equations. The mean 
EE(VCO2), with an RQ value of 0.81, was not significantly different from mean 
EE(IC) and the EE(VCO2) had a lower RMSE compared to the other predictive 
equations. The EE(VCO2) had accurate estimates in 89% of the patients, 
significantly better than the predictive equations. 
The sensitivity analysis showed that as long as the RQ is chosen within the range of 
published cohort values, 0.76 to 0.89, the VCO2-based calorimetry performs better 
than the predictive equations. 
 
Figure 6-1 Scatterplots for the predictive equations and the VCO2-based 
calorimetry, comparing them to IC. 
 
6.3.1. QUALITATIVE ANALYSIS OF DYNAMIC ERRORS 
Of all 18 patients, 17 were found to have constant EE during the recording period. 
Fig. 6-2 shows ten min. of data from an example patient with constant EE during 
the 30 min. recording period (patient 16). In the figure a change in ventilation is 
clearly visible. The MV is a steady state until 7.5 min. when the MV is lowered and 
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the measurement fluctuates until 10.5 min. when the MV reaches a lower steady 
state (fig 6-2A). The measurements of VCO2 and VO2 also fluctuate leading to 
changes in estimated EE for both the IC and the VCO2-based calorimetry (Fig. 6-
2B), however there is no reason to suspect that the patient’s EE changes during this 
period, so the fluctuations of EE(IC) and EE(VCO2) must be ascribed to the 
fluctuations of MV. In the 7.5 min. to 10.5 min. period, MV increases to 36% 
higher than the steady-state value at 7.5 min. This results in increases in VO2 and 
VCO2 of 22% and 34%, respectively and similar increases in EE(IC) and 
EE(VCO2) of 24% and 35%, respectively. 
  
Figure 6-2 A: Recorded values from patient 16 of VCO2, ET-CO2, VO2, and MV. B: 
EE(VCO2) and EE(IC) calculated from recorded VO2 and VCO2, including means 
of EE(VCO2) and EE(IC). Modified from ([109], Fig. 3). 
From 10.5 min. until 13.5 min. VO2 returns to the steady state value seen before the 
change in ventilation, and similarly the EE(IC) returns almost the steady state in the 
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same timeframe. However VCO2 does not return to steady state due to the 10-20 
min. equilibration time constant and as such the EE(VCO2) does not return to its 
original steady state value either. This shows that changes in MV results in similar 
changes in EE(IC) and EE(VCO2) but EE(VCO2) takes 10-20 min. or more to 
recover. 
 
6.3.2. QUANTITATIVE ANALYSIS OF DYNAMIC ERRORS  
The effects of changes in ventilation were determined for each patient with stable 
EE in the recording period. Individual values can be found in Paper IV upon which 
this chapter is based. 
Both EE(IC) and EE(VCO2) are vulnerable to changes of ventilation with a 
maximum deviation of up to 42% for instantaneous values of EE(IC) and 46% for 
instantaneous values of EE(VCO2). Both methods are equally vulnerable with no 
significant differences (t-test) between the mean of the max values for the two 
methods. This implies that instantaneous values of EE(IC) and EE(VCO2) cannot 
safely be used to assess EE. 
However the application of a five min. running average to the calculated EE(IC) 
reduced the max deviation to 18% and the Standard Deviation (SD) of the mean to 
7.5%. For EE(VCO2) the max deviation was reduced to 14% and the SD of the 
mean to 7.3%. 
Thus the introduction of a five min. running average reduced the dynamic error of 
the EE(VCO2) to a size comparable to the RMSE of EE difference. 
If practical another solution is the use of mean values from 24 hour measurements 
as this will smooth out short term errors. 
The results seem to confirm hypothesis N3: The predictive EE equations tested here 
(including the Mifflin St. Jeor equation used in Glucosafe) were all inaccurate (± 
10%) compared to IC measurements in more than 50% of the patients. In contrast 
VCO2-based calorimetry was accurate in 89% of the patients, though some caution 
should be taken when using short measurement periods. 
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CHAPTER 7. DISCUSSION AND 
CONCLUSION 
The pathophysiology of critical illness is complex and often results in stress-
hyperglycaemia which can be treated using IIT to reduce the BG to normal (or near-
normal) levels, though at the risk of hypoglycaemic events. 
In the introduction of this thesis a set of hypotheses regarding the treatments of 
stress-hyperglycaemia (hypotheses G1, G2, and G3) and nutritional support 
(hypotheses N1, N2, and N3) for the critically ill patient was formulated. Evidence 
concerning these hypotheses in published literature and the research presented in 
this thesis was examined. 
With regards to hypothesis G1 and G2, stating that reducing hyperglycaemia while 
avoiding hypoglycaemia is beneficial to critically ill patients, there is some 
literature support. All studies using IIT have shown reduced BG, but some have 
resulted in reduced mortality and some in increased mortality. In the studies 
showing increased mortality, it is likely due to the negative effect of substantially 
increased frequency of patients with hypoglycaemic events, overshadowing the 
positive effects of lowering the BG. A regression analysis of the studies, while not 
significant, indicates support for hypothesis G1 and G2, that reducing 
hyperglycaemia correlates with reduced mortality and that hypoglycaemia should 
be avoided as this increases mortality. 
Hypothesis G3 states that the best way to lower BG while avoiding hypoglycaemia 
is the use of a model-based decision support system. Several studies using decision 
support systems were compared and in all studies the group treated using decision 
support had lower BG, although some had increased numbers of hypoglycaemic 
events. Comparison of model-based systems and rule-based systems showed the 
model-based system to have better results, with Glucosafe showing the best results 
with lowered BG and no hypoglycaemic events, lending support to the G3 
hypothesis. In addition, clinical testing of Glucosafe has showed it to reduce 
variability of BG compared to departmental guidelines.  
Glucosafe has two major components, the model and the advice module. The 
model’s predictive accuracy can be tested and improved on retrospective data, but 
testing of the advice module in principle requires a clinical trial.  To reduce the 
need for clinical trials, a method based on virtual patients was developed. The 
virtual patients were based on insulin sensitivity profiles from real patients and 
were used to evaluate different settings of the penalty functions that govern 
Glucosafe’s treatment advice. As an example of how this method can be used 
several different modification to the penalty functions was evaluated to find the 
settings, likely to produce a desired outcome in terms of mean BG and frequency of 
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hypoglycaemic events. Glucosafe with these modified settings may then be worthy 
of a new clinical trial.  
A pancreas model of endogenous insulin release was developed for the purpose of 
improving Glucosafe’s ability to predict BG and thus improving the support for the 
G3 hypothesis. As the pancreas model introduced a feedback loop into the 
Glucosafe model it was tested for stability and found to produce damped oscillation 
after sudden changes in BG. An early version of the pancreas model, the results of 
which can be found in Paper I, showed no improvement in predictive accuracy, but 
was tested on critically ill patients with high BG and with administration of large 
insulin doses. Further clinical testing is needed to investigate if the pancreas model 
improves predictive accuracy in patients who are recovering from critical illness. 
The hypotheses stated that nutritional support should target 100% of the patient’s 
EE (N1) without overfeeding, to avoid or lessen caloric debt, except in the first few 
days (N2) where the body catabolism provides the necessary substrates to cover 
energy needs. There is support for not overfeeding patients as this has been shown 
this to have deleterious effects and although there are studies advocating 
underfeeding patients, the American, European, and Canadian guidelines for 
nutrition support the N1 hypothesis that nutritional support should target 100% of a 
patient’s EE to avoid or lessen caloric debt. With regards to restricting feeding in 
the first few days, there is no counter indication to the N2 hypothesis that nutrition 
should be reduced in the first few days where the body catabolism provides the 
necessary substrates to cover energy needs. 
However, regardless of the nutritional target being 100% of EE of less, an accurate 
estimation of a patient’s EE is needed.  
Both literature reviews of predictive equations and the results shown in Paper IV 
shows that predictive equations are often inaccurate and over- or underestimate 
patients’ EE compared to IC, which is considered the golden standard of estimating 
EE. The VCO2-based calorimetry results presented here shows that VCO2-based 
calorimetry gives EE estimates significantly better than predictive equations. A 
sensitivity analysis showed that as long as the RQ value used in the equation for 
VCO2-based calorimetry is within the published range of average cohort values, 
0.76 to 0.89, the VCO2-based calorimetry performs better than the predictive 
equations. There are some problems in using only VCO2 as a measure for EE, as 
changes in ventilation which result in VCO2 not matching metabolically produced 
CO2, results in EE estimation errors lasting up to 20 min. due the CO2 equilibration 
time constant. Solutions to this is either the application of a running average of five 
min. or more to the measurements if the measurement period is short, or the use of 
the mean values from 24 hour measurements if possible. 
The use of VCO2-based calorimetry has been shown in other studies to work in 
children [110] and adults [91] with patients specific RQ values estimated from the 
nutrition. The results presented here and those in literature support the N3 
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hypothesis and indicate that VCO2-based calorimetry should be favoured over 
predictive equations when estimating a patient’s EE. 
In conclusion there seems to be support for, or no direct evidence to oppose, the 6 
hypotheses stated in the introduction, either through published literature or the work 
presented in the thesis. 
 
7.1. FUTURE WORK 
There are three major points of future work to be addressed, all of which involve 
clinical testing of Glucosafe. Glucosafe has thus far been clinically tested for the 
ability to safely lower BG but the hypotheses and modification to Glucosafe 
presented in this thesis has not been clinically tested yet. There is a need for clinical 
testing to prove that using Glucosafe lowers mortality, the clinical testing of the 
pancreas model, and Clinical testing of hypothesis N1 and N2 to find the optimal 
nutritional treatment for the critically ill. 
The regression analysis performed on several studies indicated that lowering BG 
without increasing hypoglycaemic events decreases mortality. While clinical 
studies of Glucosafe have not evaluated mortality, Glucosafe has been shown to 
lower BG without any hypoglycaemic events and therefore the expectation is that 
using Glucosafe results in lowered mortality. There is however a need to clinically 
test this, to prove the expectations. In addition such clinical testing may also show  
computer-based system have the added benefit of making it easier to keep track of 
current and previous treatment, both in terms of glycaemic control, but also for 
nutritional support. A computerized system would also make it easier to track 
nutritional inputs, patient EE, and caloric debt, on a continuous basis, compared to 
paper-based systems. 
There is also a need to clinically validate the pancreas model on patients that are 
recovering from critical illness. The model has thus far been tested for stability but 
there is need of a study to test if the addition of the pancreas model, not just 
improves the predictive capabilities of Glucosafe, but if Glucosafe is able to model 
less critically ill patients. 
As hypotheses N1 and N2 has not been proven and as there is not a consensus on 
the optimal nutritional treatment for critically ill, there is a need to clinically test the 
hypotheses, if permissive underfeeding in the early state of critical illness and then 
targeting the patients EE later improves patient outcome, including an accurate 
estimation of patient EE using either IC or VCO2-based calorimetry. 
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